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INTRODUCTION: 
 
The siddha system of medicine is one of the ancient systems contemporaneous 
with those of the submerged lands, Egyptian, Mesopotamian, Chinese and Grecian 
medicines. The unique nature of this system is its continuous service to humanity for 
more than five thousand years
[2]
.Tamil nadu the home of the siddhar was a vast 
continent several million of year ago 
[3]
. "Siddhargal" or Siddhars were the premier 
scientists of ancient days. Siddhars, mainly from Southern India laid the foundation 
for this system of medication 
[4]
. There were 18 important Siddhars in olden days and 
they developed this system of medicine. Hence, it is called Siddha medicine. The 
word Siddha comes from the word Siddhi which means an object to be attained 
perfection or heavenly bliss
[5]
. 
Siddha medicine means medicine that is perfect. Siddha medicine is claimed 
to revitalize and rejuvenate dysfunctional organs that cause the disease and to 
maintain the ratio of mukkutram Vaatham, Pitham and Kabam. According to the 
Siddha medicine, various psychological and physiological functions of the body are 
attributed to the combination of sevenelements: 
 First is saaram (plasma) responsible for growth, development and 
nourishment; 
 Second is senneer(blood) responsible for nourishing muscles, 
imparting color and improvingintellect; 
 The third is oon(muscle) responsible for shape of thebody; 
 Fourth is kozhuppu (fatty tissue) responsible for oil balance and 
lubricatingjoints; 
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 Fifth is elumbu (bone) responsible for body structure and posture and 
movement; 
 Sixth is moolai (bone marrow) responsible for formation of blood 
corpuscles; 
 And the last is sukkilam/suronitham (sperm/ova) responsible for 
reproduction 
It is assumed that when the normal equilibrium of the three humors (Vadham, 
Pitham and Kabam) is disturbed, disease is caused. The factors, which assumed to 
affect this equilibrium, are environment, climatic conditions, diet, physical activities, 
and stress. Under normal conditions, the ratio between these three humors i.e.: 
(Vadham, Pitham, Kabam) 1:1/2: ¼ respectively 
[6]
. 
The siddha medicine given to Herbal products, Inorganic substance and 
Animal products (thavara, thathu, sangama things).The drugs used in siddha medicine 
were classified on the basis of five properties 
 Suvai (taste), 
 Gunam(character), 
 Veeryam(potency), 
 Pirivu(class) 
 And Mahimai(action). 
 
According to their mode of application, the siddha medicines could be 
categorized into two classes 
[6]
: 
 Internal medicine was used through the oral route and further classified into 
32 categories based on their form, methods of preparation, shelf-life,etc.
 External medicine includes certain forms of drugs and also certain applications 
(such  as  nasal,  eye  and  ear  drops),  and  also   certain  procedures  (such   
as leech application). It also classified into 32 categories.
According to the siddha medicine system, diet and lifestyle play a major role, 
not only in health but also in curing diseases. This concept of the siddha medicine is 
termed as pathiyam and apathiyam, which is essentially a list of "do's and don'ts"
[7]
. 
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The art of living depends upon several factors including maintenance of 
heredity with healthy progeny. Healthy progeny depends upon healthy gametes from 
both male and female partners of conjugated life style. 
Infertility bears a social stigma. According to The World Health Organization 
(WHO)estimatesthat60to80millioncouplesworldwidecurrentlysufferfrominfertility[8]. 
Infertilityvariesacrossregionsoftheworldandisestimatedtoaffect8to12percentof couples 
worldwide [9][10]. It means failure of a couple to become parent after one year of 
successful married life. Male infertility is commonly due to deficiencies in the semen, 
and semen quality is used as a surrogate measure of malefecundity.
[11]
 
Male infertility is a vexing clinical problem. The incidence of male infertility varies in 
different region. The incidence of infertility among males 40%, females 40%, both 
sex 20%
[12]
. 
To Generate new knowledge on Siddha Andrology to fertility regulation and 
Endocrine disorders ancient Siddha literatures describes many safe and effective 
drugs identified by Siddhars for thousands of years. 
In our Siddha System of Medicine According to Thirumoolar Yogam 
(Asanams)Asanam(Yogam) one of the  Astaanga yogam .Yogasanam  to fight all the 
emotional and psychological traumas by proving a calm and peaceful state of health 
,which ultimately boosts well-functioning of reproductive system. 
A quiet,stable mind and body promotes fertility.There are certain yogasanam that 
especially target the reproductive organs and the pelvic area. 
Men are subject to infertility problems like low sperm count ,which is quiet often 
related to high stress levels.Regular Yogam practice helps release stress and most 
importantly yoga can help regain sexual stamina.So I am eager to conduct a 
successful clinical study in THETRAN ILAGAM (INTERNAL) and YOGAM 
THERAPY for Aanmaladu (Male infertility)         
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AIM: 
AIM & OBJECTIVE 
 
 
 To evaluate the therapeutic efficacy of  Thetran Ilagam and Yogam 
therapy in the Aan maladu (Male infertility) .    
OBJECTIVE: 
 
 To evaluate the therapeutic efficacy of Thetran Ilagamin Aan maladu 
(Male infertility) to increase the sperm concentration, viscosity of 
semen and to reduce premature ejaculation, nocturnal emission in 
AANMALADU. 
 To evaluate the safety profile of the trial drug Thetran Ilagan 
 
 To collect the authorized measures and review the ideas of Aan maladu 
in Siddha and modernliteratures. 
 To have an idea about the relation of the disease with age, habits, 
occupation, economic states, family history and climaticconditions. 
 To expose the efficacy of siddhars diagnostic principles such as 
mukkutram, envagai thervugal, eazhu udalthadhukkal, neerkuri and 
neikkuri. 
 To have detailed clinicalinvestigations. 
 To have a clinical trial on the disease “AAN MALADU” with the 
siddha herbal formulation of “THETRAN ILAGAM”. 
 Toevaluate the, 
 
Toxicity study [acute & sub-chronic] 
Sexual Health Score 
Yogam therapy 
Bio –statistical analysis 
 To handle the modern parameters to confirm the diagnosis and 
prognosis of thestudy. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
 
 
 
FORMATION OF FETUS COMBINES WITH PANJABOOTHAM: 
 
 
 
[13] 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ovum consists of the element earth, whereas the sperm consists of fire and 
air, the uterine wall nourishes it has water and uterine cavity is one of the element of 
space. Therefore in the formation of fetus all the five elements combine and create it. 
DETERMINATION OF GENDER OF EMBRYO: 
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At the time of copulation if the male dominates then it is male, if the female 
dominates then it is female, if the male and the female are equal then the child was  
intersex gender or an eunuch. 
 
 
 
 
 
 
 
 
 
 
 
 
THE ROLE OF VAAYUS IN FERTILIZATION: 
 
 
 
 
 
 
Abanan stays outside the zygote and protect it. The pranan goes along with 
spermatozoa and bisects the size of the zygote
 [14][17]
 . 
REASON FOR MALADU IN SIDDHA LITERATURE: 
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[19] 
 
 
 
According to agathiyar uyar gnanam, at the time of copulation the following 
11 principle‟ s (the five organs of action, the five organs of perception, and soul) tobe 
concentrated by both thepartners
[14]
. 
 
 
 
 
 
 
 
 
In  these forces may act in an abnormal manner and cause diseases thereby. 
Similarly, in the great organisms of the cosmos, they may act abnormally likewise and 
bring about diseases on earth and its atmospheric conditions such as earthquakes, 
storms, lightning, and rain-falls resulting in floods or inundations and so on. Again, 
the quality of life found in the elements constituting the blood of man corresponds to 
the quality of the invisible influences radiating from mars. If the soul- essentials that 
characterize the influences of Venus do not exist, the natural instincts that cause 
men and animals to propagate their species would cease to operate; because all 
beings in the universe are sympathetically connected with the only one universal 
principle of life from Venus resulting in love between two people of the 
oppositesex
[20][21]
. 
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AAN MALADU 
 
 
 
[22][23] 
 
 
 
SUKKILA VATHAM: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[24] 
 
 
 
Emaciation, constipation, oliguria, bleeding from the nose, phlegm 
accumulation due to increased kapham, breathlessness, loss of taste. All the symptoms 
are associated with affected sukkilam, according to yugi
[25]
. 
 
 
 
 
 
 
 
AAN MALADU: 
 
According to T.V.Sambasivam pillai dictionary, The semen in such cause was  
devoid of sweetness and life and float on the surface of water. The urine also was  
frothy. Such man is incapable to impregnate women
[27]
. 
-T.V.Sambasivam pillai dictionary page no 345. 
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FORMATION OF VINDHU (SEMEN): 
 
 
 
 
 
 
 
 
 
 
[28] 
 
. 834 
 
 
 
[29] 
 
. 839 
 
According to siddhars 1 drop of venner made from 80 drops of senner (blood). 
1drop of vindhu made from 80 drops of venner. So 6400 drops of senner (blood) 
needed to make one drop of vindhu
[30]
. 
 
 
AAN MALADU GUNAM: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[31] 
 
. 176 
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According to yugi and arivaiyar sinthamani 
 
 Lack of sweetness insemen
 Buoyancy onwater
 Absence ofvirility
 Frothymaturation
 
The above told character of semen mainly contributes infertile man. 
 
AETIOLOGY: 
 
 
 
 
[33] 
 
 
 
 
 
 
15  
MALE INFERTILITY DUE TO INFECTIONS: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[34][35] 
 
 
 
 
 
 
 
 
 
 
 
 
 
The complications of the karumpanisai ammai are, 
 
-Death of sperm cells inmale 
-Abortion in pregnantwomen 
-Produce sterility in both men and women
[35]
. 
 
 
MALE INFERTILITY DUE TO TRAUMATIC LESIONS: 
 
 
 
[36]. 
 
 
 
 
 
[37]. 
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DIAGNOSTIC METHODS IN SIDDHA SYSTEM: 
 
UDAL KATTUGAL: (SEVEN PHYSICAL CONSTITUENTS) 
1. SAARAM – CHYLE (PLASMA): 
It is responsible for the growth & development. It keeps the individual in good 
spirit and nourishes the blood. 
In Aan Maladu, Saaram affected. 
2. SENNEER –BLOOD: 
Blood imparts color to the body and nourishes the muscle for the ability. 
3. OON –MUSCLE: 
Gives shape to the body. 
4. KOZHUPPU –FAT: 
It helps in lubricating the different organs and maintains oily matter of the 
body. 
5. ENBU –BONE: 
It supports the system and responsible for the posture movement of the body. 
6. MOOLAI –MARROW: 
It fills the bone cavity, nourishes semen and imparts strength, endurance and 
shiny appearance. 
7. SUKKILAM(SPERM): 
It is responsible for the reproduction
[38]
. 
 
In Aan Maladu, Sukkilam affected. 
 
At the time of copulation, the semen is ejaculated. The prostatic fluid gives  
the semen a milky appearance. In the early minutes after ejaculation, the sperm 
remains immotile, possibly because of the viscosity of the coagulum. As the 
coagulum dissolves the sperm become highlymotile. 
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At the time of copulation insufficient quantity of semen is ejaculated with 
pain, pricking pain in the scrotum, irritation of thepenis
[40]
. 
 
 
 
 
 
[41]. 
 
Examine the semen: 
If the semen is, 
1. White and akin to the butter, it isexcellent. 
2. White and akin to curd, it is verygood. 
3. White and akin to the milk, it isgood. 
4. White and akin to the butter milk, it isfair 
5. Akin to the honey in color and consistency, it isaverage. 
6. Akin to the ghee in color and weight, it ispoor. 
7. Akin to the toddy is color and weight, it is verypoor. 
8. Akin to the water, it is verybad[42]. 
 
 
 
 
 
 
 
 
 
 
”[43]. 
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Uyir thathukkal / Mukkutram: 
These are all the main three pillars which functioning the body with an 
equilibrium state. Any disturbance in that state leads to diseased condition in our 
body. 
The three pillars are, 
 
 
1. Vali 
2. Azhal 
3. Iyam 
 
 
1. Vali or Vaayu: 
Vali is not mere wind, but also that which causes motion, energy and sensation 
of every cell in the body. Vaayu relates to nerve force. It is responsible for all 
movements in the mind and the body. In human body it controls the Gnanendriyam 
(sensory actions) & Kanmendriyam (motor activities) 
Vali generally lives in, 
Abanan, Edakalai, Kamakodi, Undhiyin Keezh Moolam, Hip region, Bones, Muscles, 
Nerves, Joints, Skin, Hair follicles, Stools. 
Varieties of Vali: 
According to their location and functions they are classified into 10 types. 
1. Uyirkkaal (Pranan) 
2. Kezhnokkum Kaal(Abanan) 
3. Paravukaal(Viyanan) 
4. Melnokkum Kaal(Udhanan) 
5. Nadukkaal(Samanan) 
6. Naagan 
7. Koorman 
8. Kirugaran 
9. Devadhathan 
10. Thananjeyan 
1. Uyirkkaal (Pranan) (Heart Centre) 
It regulates the respiratory, cardiac and digestive system. By joining with 
pingalai it forms azhal naadi. It is responsible for bio comfusion in the body. 
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2. Kezhnokkum Kaal (Abanan) (MooladharamCentre) 
It regulates the defecation, micturition, menstruation, parturition and 
ejaculation. It corresponds to the pelvic plexus and the lower part of the gut. 
3. Paravukaal (Viyanan) (fore headcenter) 
It spreads all over the body and all nerve endings. It regulates constriction and 
relaxation of the voluntary and involuntary muscles. The neurological problems were 
due to this Vaayu. It spreads the nutrients to all over the body from the digested food. 
4. Melnokkum kaal(Udhanan) 
It is responsible for speech, vomiting, hiccough and sneeze. 
5. Nadukkaal(Samanan): 
It is responsible for digestion and it spreads the nutrients to all over the body. 
Joining with suzhumunai it forms the Kabha naadi. It neutralizes the other four 
Vaayus. 
6. Naagam: 
It is responsible for the intelligence and derangement of this Vaayu causes 
impaired memory. It helps to opening and closure of eyelids. 
7. Koorman: 
This is responsible for the vision, Yawning and Lacrimal secretions. 
8. Kirugaran: 
It is responsible for salivation, nasal secretion, hunger, sneeze, cough and 
concentration. 
9. Devadhathan: 
It is responsible for laziness and anger. 
10. Thananjeyan: 
It produces swelling all over the body and leaves from cranium only after the 
3rd day after death. It is responsible for the decay of the body after death
[44]
. 
In Aan Maladu, Kezhnokkum Kaal & Paravukaal affected. 
II.Azhal: 
This is nothing but the characteristics of fire such as burning, boiling and 
heating etc. It corresponds to the functions so thermo genesis production of heat 
necessary to maintain integrity of the human circulatory system. Azhal is classified 
into 5 types. In mainly governs enzymes & hormones. 
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Azhal lives in: 
Between heart & the navel, Sweat, lymph, blood, stomach, urinary bladder, saliva eye 
and skin 
In Aan Maladu, Sathaga Pitham affected. 
Name Location Function 
1. Akku anal (Analagam) 
Stomach, Small intestine Dissolvent& Digestive 
2. Vanna eri(Ranjagam) 
Liver, Spleen, Stomach Coloring, Pleasing, Gratifying 
3. Attralangi(Sathagam) 
Heart Effective efficient 
4. Nokku Azhal (Alosagam) 
Eyes seeing, consideration 
5. Ollolithee(Prasagam) 
Skin Complexion of the skin
[44]
. 
Iyyam: 
It imparts moisture. Iyam is located in samanan semen, head, tongue, flat, 
bone marrow, blood, nose, chest, nerves, brain, large intestine, eyes, stomach & 
pancreas. 
Name Location Function 
1. Alli Iyam(Avalambagam) 
Lung supports all the others 
2. Neerpi Iyam(KiIethagam) 
Stomach Moistens and nourishes the food 
3. Suvaikanna Iyam(Pothagam) 
Tongue Take care of perception 
4. Niraivu Iyam(Tharpagam) 
Head Refrigerant effect toeyes 
5. Ondri Iyam(Santhigam) 
Joints Stability, Lubrication movements of joint
[44]
. 
 
In Aan Maladu, Tharpagam & Santhigam affected. 
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ENN VAGAI THERVUGAL 
 
 
 
 
 
 
 
[45] 
 
 
 
It is the unique and special method in siddha 
 
Envagai thervugal is the specialty of siddha diagnosis. These are the instruments 
for the physician to diagnose disease. 
NAADI: 
 
 
 
 
[46] 
 
The three uyir thaadukkal felt through the pulse is called naadi 
 
 
Naadi  Vaayu Uyir thathu Ratio 
Edakalai + Abanan - Vatham – 1 
Pinkalai + Piranan - Pitham – ½ 
Suzhumunai + Samanan - Kapam – ¼ 
 
PARISAM: 
Observations by touch, temperature, sensory impairments, masses, nodes, 
swelling and texture of the skin, pain, hardness, edematous and dullness shall be 
noted. 
NAA: 
Signs and symptoms in the tongue are considered here. Size, appearance, 
thickness, color (pigmented, mangenta) fissured (longitudinal, transverse) coated, 
geographical patches, oral hairy leukoplakia, candida, aphthous ulcer, sense of taste, 
saliva secretion. 
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NIRAM: 
The color of skin is mainly considered here but also the change in other 
organs. 
MOZHI: 
The change in the normal sound of voice mainly uratha olli (Valithel), 
thazhntha olli (Melithal), physiological and mental status can also be noted during 
conversation. 
VIZHI: 
Color, warm, burning sensation, irritation, visual perception 
MALAM: 
Nature, quantity, color, odour, froth, consistency are noted. 
MOOTHIRAM: 
The urine examination is classified into two types. 
NEERKKURI: 
 
[47] 
 
 
 
Urine is to be observed for the following characters 
 Niram(color) 
 Edai (specific gravity) 
 Manam(smell) 
 Nurai(froth) 
 Enjal(deposit)[48] 
 
NEIKKURI: 
It is an important test to assess the predominantly affected humour. 
 
 
 
 
 
[47][48] 
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On the day before the urine test one should take food, consisting of all the six 
tastes at the regular time based on one’s digestive fire; after a sound overnight sleep, 
urine should be collected in a glass ware and the test should be done before 90 
minutes from dawn. A drop of oil is dropped at the center of urine (bowl) without any 
shake. It should be ensured that the Sunlight falls on it, but is not disturbed by the 
wind. A keen observation of the oil drop suggests the condition of the patient. If the 
oil drop takes the shape of a snake, it indicates Vaadha disease. If it spreads like a ring 
it indicates Pitha and if it stands like a pearl it indicates Kaba disease. If there is a 
combined shape like a ring in a snake, or snake in the ring, snake and a pearl or a 
pearl in the ring, it indicates combined derangement of humors. White layer starts 
with disturbed Azhal and eventually involves all the three uyir thathus-thus resulting 
in various patterns of oil spread in the urinesurface. 
 
NOI NEEKAM (TREATMENT): 
In Siddha system the main aim of treatment is not only for the removal of 
Physical illness but also the mental illness. Treatment is considered with prevention 
and improvement of the general body condition (rejuvenation) also. This is said as 
follows 
Kappu - Prevention 
Neekkam -Treatment – curative 
Niraivu -Restoration –promotive 
While treating the disease the following principles must be noted. So it is 
essential to diagnosis properly to know about the etiology, the nature of the patient, 
the severity of illness, the seasons and the time of the occurrence of thedisease. 
LINE OF TREATMENT: 
1. To bring the three Kutrams inequilibrium 
2. Medicine(Internal) 
3. Diet andadvise 
1. TO BRING THE THREE KUTRAMS IN EQUILIBRIUM: 
Since Siddha system of medicine is based on Mukkutra theory, the purgation 
(Kalichal Maruthuvam) was given by for the vitiation of three humours. Agasthiyar 
Kuzhambu 65mg was administrated at early morning as a purgative in the prior day of 
treatment. 
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YOGA THERAPY FOR MALE INFERTILITY: 
Yoga has been practiced in India for a number of centuries. There are several methods of yogic practice 
originating from different school of thoughts. Yogic exercises improve the psychological functions of the 
individual
[49]
. I shall deal with only such asanaas are useful in curing ailments and maintaining good health for 
the male infertility. These group  of Asanams are recommended for 45 mins to 1hr  
 (Daily morning or Evening) (morning 6am  and evening 6pm ) 
 
SARVANGASANAM: 
 
It is stimulates the pituitary and thymus glands and keeps the prostate gland 
healthy. This asana keeps the sex glands healthy. Sexual weakness in the case of male 
can be overcome by the practice of asana
[49]
. 
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MACHASANAM: 
 
 
 
 
 
 
 
Improving the functioning of Thyroid gland and Improve Immune system  
 
Increases bloodflow to genital areas 
 
Imcrease vitality and preserves youthfullness. 
 
SAVASANAM:  
Savasanam is a Powerful Tranquilizer. It pacifies the body and a mind by eliminating muscular, 
Nervous, Mental and Emotional tension almost immediately[49]. 
 
DHANURASANA: 
 
 
 
 
It improves functions of the reproductive system in male and female[50].
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SHALABASANAM: 
 
It promotes fresh Blood supply to Urogenital organs. It will effectively cure 
Nocturnal discharges and sexual debility
[49]
. 
 
PASCHIMOTTASANAM: 
1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Relieves dyspepsia,Strengthens urogenital system
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MAHAMUDRA: 
 
 
 
 
 
 
 
 
 
 
 
 
 
It help in the enhancing concentration  power  and increasing self-confidence. 
 
 
 
 
PRANAYAMA: 
• It gives a feeling of freshness, energy and lightness of body and mind. 
• Strengthens the lungs. Increases its capacity and cures the disorders. 
• Digestion is improved. 
• Excretory system is stimulated. Toxins are removed from the body. 
• Skin tone is well maintained. 
• All the endocrine glands are stimulated. 
• It makes the nervous system more energetic. 
• It increases concentration and helps meditation 
 
 
COOLING PRANAYAMA: 
They are Cooling Pranayamas because of their cooling effect, and the help in calming  
down the mind by removing the mental anxiety & tension.
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DIET AND ADVICE: 
DIET TO BE ADDED 
 
 
 
       
 
VEGETARIAN DIET: 
  
  
  
  

 [60]. 
NON - VEGETARIAN DIET: 


 [60]. 
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DIETS TO BE RESTRICTED: 






 [60]. 
 
 
 
PATIENTS ADVICED TO FOLLOW: 
  
  
  
  
  
 [60]. 
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MODERN ASPECT 
Male Infertility 
According to statistics collected from The World Health Organization (WHO) 
estimates that 60 to 80 million couples worldwide currently suffer from infertility
[7]
. 
The prevalence of infertility in the general population is 15%–20%. Of this, the male 
factor is responsible for 20%–40%[61]. In Indian couples seeking treatment, the male 
factor is the cause in approximately 23%
[62]
. In a World Health Organization 
multicenter study, 45% of infertile men were found to have either oligo-zoospermia or 
azoospermia
[63]
. A study from a tertiary care hospital in India reported 58% 
azoospermia and 24% oligozoospermia in infertile men
[64]
. 
Infertility can be of three different Types: 
Primary Infertility: 
When a woman has never achieved conception in her life it is known as 
Primary Infertility. 
Secondary Infertility: 
When a woman has given birth to a child in the past but is facing difficulty to 
conceive again it is called Secondary Infertility. 
Recurrent Miscarriage: 
Women who experience recurrent miscarriages may also receive a diagnosis 
of infertility if they experience two or more successive miscarriages. While 
miscarriage is not uncommon (occurring in up to 25% of recognized pregnancies), 
less than 5% of women will experience two miscarriages in a row, and less than 1% 
three or more successivemiscarriages. 
Etiology: 
Factors relating to male infertility include:- 
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
Pre testicular causes: 
a) Hypothalamopitutarydiseases 
b) Hyperprolactinemia 
c) Isolated FSHdeficiency 
d) Congenital hypogonadrotrophicsyndrome 
e) Exogenous hormones (estrogen- androgenexcess) 
f) Glucocorticoidexcess 
g) Hyper – andhypothyroidism 
h) Drugs like phennytoin, androgens and estrogens 
i) Alcohol,smoking 
j) Strenuous riding (bicycle riding, horsebackriding) 
Testicular Factors: 
a) Testicular atrophy 
b) Cryptorchidism 
c) Varicocele 
d) Trauma 
e) Hydrocele 
f) Mumps 
g) Malaria 
h) Spermatogenesisarrest 
Post Testicular Causes: 
a) Vas deferensobstruction 
b) Lack of Vas deferens, often related to genetic markers for CysticFibrosis 
c) Infection, e.g.prostatitis 
d) Retrogradeejaculation 
e) Hypospadias 
f) Impotence 
g) Acrosomal defect/egg penetration defect[65]. 
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ANATOMY OF MALE REPRODUCTIVE ORGANS 
 
The male reproductive system includes the testis, epididymis, ductus (vas) deferens, 
seminal vesicles, prostate and penis 
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TESTES: 
 
The testes are the primary reproductive organs or gonads in the male. They 
are ovoid reproductive and endocrine organs responsible for sperm production. 
They are suspended in the scrotum by scrotal tissues including the dartos muscle 
and the spermatic cords. Average testicular dimensions are 4-5 cm in length, 2.5 
cm in breadth and 3cm in anterio posterior diameter; their weight varies from 10.5- 
14g. The left testis usually lies lower than the right testis. Each testis lies obliquely 
within the scrotum, its upper pole tilted anterolaterally and the lower 
posteromedially. 
 
The testis is invested by three coats; 
Tunica vaginalis 
Tunica albuginea 
Tunica 
vasculosaTUNICA 
VAGINALIS 
It is the lower end of the peritoneal process vaginalis, whose formation 
proceeds the decent of the fetal testis from the abdomen to the scrotum. The 
visceral layer covers all the aspect of the testis except most of the posterior aspect. 
The more extensive parietal layer reaches below the testis and ascends in front of 
and medial to the spermatic cord. The Inner surface of the tunica vaginalis has a 
smooth, moist mesothelium the potential space between its visceral and parietal 
layers is termed the cavity of the tunica vaginalis. 
TUNICA ALBUGINEA 
 
It is a dense, bluish white covering for the testis. It is composed mainly of 
interlacing bundles of collagen fibres. It is covered externally by the visceral layer 
of the tunica vaginalis, except at the epididymal head and tail and the posterior 
aspect of the testis, where vessels and nerves enter. It covers the tunica vasculosa 
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and, at the posterior borders of the testis, project in to the testicular interior as a 
thick, incomplete fibrous septum, the mediastinum testis. 
TUNICA VASCULOSA 
 
It contains a plexus of blood vessels and delicate loose connective tissue, 
and extend over the internal aspect of the tunica albuginea, covering the septa and 
therefore all the testicular lobules. 
EPIDIDYMIS 
 
The epididymis lies posteriorly and slight lateral to the testis, with vas 
deferens along its medial side. It has an expanded head superiorly, a body and a 
tail.Itsoveralllengthis6-7cmanditconsistsofthesingleconvolutedductus 
epididymis formed by the union of the efferent ducts of the testis, which attach to 
the rete testis. From the tail the vas deferens ascends medially to the deep inguinal 
ring, within the spermatic cord
[66]
. 
 
TESTICULAR AND EPIDIDYAMAL APPENDICES 
 
At the Upper extremities of the testis and epididymis are two small stalked 
bodies the appendix testes and appendix epididymis. They are developmental 
remnants of the para meso nephric ducts (mullerian) ducts and meso nephrons 
respectively. 
TESTICULAR TORSION 
 
The testis and epididymis are usually fixed to their surrounding tissues. In 
some patients this fixation may be insufficient, a condition which allows the 
structures to twist within the tunica vaginalis. This is termed testicular torsion and 
normally results in severe scrotal pain. Fertility may be affected by an episode of 
torsion. 
SEMINAL VESICLES: 
 
The two seminal vesicles are sacculated, contorted tubes located between 
the bladder and rectum. Each vesicle is 5 cm long, somewhat pyramidal, the base 
being directed up and posterolaterally. Essentially the seminal vesicle is a single 
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coiled tube with irregular diverticula. The coils and the diverticula are connected 
by the fibrous tissue. The diameter of the tube is 3-4 mm and its uncoiled length is 
10-15cm
[67]
. 
VAS DEFERENS: 
 
It is a muscular tube, 45 cm long, which conveys sperm to the ejaculatory 
ducts, and its distal continuation of the epididymis, starting at the epididymal tail. 
At first it is very tortuous, but it becomes straighter, and ascends along the 
posterior aspect of the testis. From the superior pole of the testis it ascends in the 
posterior part of the spermatic cord, and traverses the inguinal canal. At the 
internal inguinal ring the vas deferens leaves the cord, curves round the lateral side 
of the inferior epigastric artery. It then turns back and inclines slightly down and 
obliquelyacrosstheexternaliliacvesselstoenterthelesserpelvis.Itcrossesthe 
ureter and bends acutely to pass anteromedially between the posterior surface of 
the bladder and upper pole of the seminal vesicle. It finally descends to the base of 
the prostate, where it joins to the duct of the seminal vesicle at an acute angle to 
form the ejaculatoryduct
[67]
. 
EJACULATORYDUCTS 
 
The ejaculatory ducts are formed on each side by the union of the duct of 
the seminal vesicle with ampulla of the vas. Each is almost 2 cm in length, starts 
from the base of the prostate, runs anteroinferiorly between its median right or left 
lobes. 
SPERMATIC CORD: 
 
At the testis traverse the abdominal wall into the scrotum during early life, 
it carries its vessels, nerves and vas deferens with it. These meet at the deep 
inguinal ring to form the spermatic cord, which suspends the testis in the scrotum 
and extends from the deep inguinal ring to the posterior aspect of the testis. The 
left cord is a little longer than the right. Between the superficial ring and testis the 
cord is anterior to the rounded tendon of adductor longus. The spermatic cord 
contains the vas deferens, testicular artery and veins, cremastric artery and artery to 
the vas deferens, genital branches of the genitofemoral nerve, cremastric nerve and 
sympathetic components of the testicularplexus. 
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Aberrant ductless: 
 
A narrow, blind caudal aberrant ductile often occurs usually connected with 
the caudal part of the epididymal duct or with the start of the vas deference. 
Paradidymis: 
 
The paradidymis is a small collection of convoluted tubules found 
anteriorly in the spermatic cord above the epididymalhead. 
SCROTUM 
 
The scrotum is a cutaneous fibro muscular sac containing the testes and 
lower parts of the spermatic cords. It hangs below the pubic symphysis between 
theanteromedialaspectsofthethighs.Itisdividedintorightandlefthalvesbya 
cutaneous raphe, which continues ventrally to the inferior penile surface and 
dorsally along the midline of the perineum to the anus. 
It consists of skin, dartos muscle and external spermatic, cremastric and 
internal spermatic fasciae. The scrotal skin is thin, pigmented and often rugose. It 
bears thinly scattered, crisp hairs. It has sebaceous glands, numerous sweat glands, 
pigment cells and nerve endings. The left side of the scrotum is usually lower 
because the left spermatic cord is longer. 
 
PENIS 
 
The penis is the male organ of copulation, consists of an attached root in 
the perineum and a free, normally pendulous body which is completely enveloped 
in skin. The penile skin is remarkably thin, dark and loosely connected to the 
tunica albuginea. At the corona of the penis it is folded to form the prepuce or 
foreskins, which variably overlap the glans. The prepuce and glans penis enclose a 
potential cleft, the preputial sac and the two shallow fossae flank thefrenulum. 
Root of the penis: 
The root of the penis is situated in the superficial perineal pouch. It is 
consists of three masses of erectile tissue in the urogenital triangle, namely the two 
crura and one bulb, each crus is firmly attached to the margins of the pubic arch 
and is covered by the ischiocavernosus. The blub is attached to the perineal 
38 
 
membrane in between the two crura. It is covered by thebulbospongiosus. 
Body of the penis: 
The body of the penis composed of three elongated masses of erectile 
tissue. During erection of the penis these masses become engorged with blood 
leading to considerable enlargement. When flaccid the penis is cylindrical, but 
when erect it is triangular with roundedangles. 
Corpora cavernosa: 
The corpora cavernosa of the penis form most of the body. On the urethral 
surface their combined mass has a wide median groove, adjoining the corpus 
spongiosum. 
Corpus spongiosum: 
The corpus spongiosum of the penis is traversed by the urethra. Near the 
end of the penis it expands in to a somewhat conical enlargement, called the glans 
penis
[66]
. 
 
REPRODUCTIVE AND HORMONAL FUNCTIONS OF THE MALE: 
The reproductive functions of the male can be divided in to three major 
subdivisions: 
(1) Spermatogenesis 
(2) Male sexualcycle 
(3) Regulation of male reproductive functions by varioushormones 
 
 
GAMETOGENIC FUNCTIONS OF TESTES – SPERMATOGENESIS: 
The production of gamete cells is called the gametogenic function. 
Spermatogenesis is the process by which spermatozoa are developed from the 
primitive germ cells called the spermatogonia of testis. 
STAGES OF SPERMATOGENESIS: 
Spermatogenesis occurs in four stages: 
1. Stage ofproliferation 
2. Stage ofgrowth 
3. Stage ofmaturation 
4. Stage oftransformation. 
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1. STAGE OFPROLIFERATION: 
The spermatogonia near the basement membrane of seminiferous tubule are larger. 
Each spermatogonium contains diploid number of chromosomes (23 pairs in man) 
One member of each pair is from maternal origin and the other one from paternal 
origin. During the proliferative stage, the spermatogonia divide by mitosis without 
any change in chromosomal number. During this stage, the spermatogonia migrate 
along with sertoli cells towards the lumen of seminiferoustubule. 
2. STAGE OFGROWTH: 
In this stage, the primary spermatocyte grows into a large cell. Apart from 
growth, there is no other change in spermatocytes during this stage 
3. STAGEMATURATION: 
After reaching the full size, each primary sepermatocyte quickly undergoes 
meiotic or maturation division, which occurs in two stages. 
I. First stage – two secondary spermatocytes areformed 
II. Second stage – each secondary spermatocyte divides into twospermatids. 
4. STAGE OFTRANSFORMATION: 
The spermatids do not divide further but transform into matured spermatozoa 
(sperms) by a process called spermatogenesis. 
 
STAGE OF SPERMATOGENESIS- NECESSARY HORMONES 
 
 
Stage of spermatogenesis Hormones necessary 
1. Stage of proliferation FSH, GrowthHormone 
2. Stage of growth Testosterone, Growth Hormone 
3. Stage of maturation Testosterone, Growth Hormone 
4. Stage of transformation Testosterone, Estrogen 
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ROLE OF HORMONES IN SPERMATOGENESIS: 
 
 
Spermatogenesis is influenced by many hormones which act either directly or 
indirectly. The hormones necessary for spermatogenesis are, 
1. Follicle stimulating hormone(FSH) 
2. Testosterone 
3. Estrogen 
4. Luteinizing hormone(LH) 
5. Growth hormone(GH) 
 
1. FSH: 
FSH is responsible for the intiation of spermatogenesis. It binds with Sertoli 
cells and induces the proliferation of spermatogonia. It also stimulates formation of 
estrogen and androgen binding protein from sertoli cells. 
2. TESTOSTERONE: 
It stimulates the spermatogenesis. It is also necessary for the formation of 
secondary spermatocyte from primary spermatocyte. 
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ESTROGEN: 
This is secreted by Sertoli Cells. This is also necessary for spermeogenesis. 
3. LH: 
 
 
4. GH: 
This hormone is essential for the secretion of testosterone from Leydig cells. 
GH is essential for back ground metabolism of testis. It is also necessary for 
proliferation of spermatogonia. In pituitary dwarfs, the spermatogenesis is severely 
affected. 
MATURATION OF SPERM IN THE EPIDIDYMIS: 
After formation in the seminiferous tubules, the sperm require several days to 
pass through the 6-meter long tubule of the epididymis. Sperm removed from the 
seminiferous tubules and from the early portions of the epididymis are non-motile, 
they cannot fertilize an ovum. However after the sperm have been in epididymis for 
some 18 to 24 hours they develop the capability of motility even though several 
inhibitory proteins in the epididymal fluid still prevent final motility until after 
ejaculation. 
STORAGE OF SPERM: 
The two testes of the human adult form up to 120 million sperm each day. A 
small quantity of these can be stored in the epididymis but most are stored in the vas 
deferens. They can remain stored maintaining their fertility for at least a month. 
During this time they are kept in a deeply suppressed inactive state by multiple 
inhibitory substances in the secretions of the duct. Conversely with a high level of 
sexual activity and ejaculations storage may be no longer than a few days. After 
ejaculation the sperm become motile and they also become capable of fertilizing the 
ovum a process called maturation. The sertoli cells and the epithelium of the 
epididymis secrete a special nutrient fluid that is ejaculated along with sperm. This 
fluid contains hormones and enzymes and special nutrients that are essential for sperm 
maturation. 
PHYSIOLOGY OF THE MATURE SPERM: 
The activity of sperm is greatly enhanced in a neutral and slightly alkaline 
medium as exists in the ejaculated semen but it is greatly depressed in a mildly acidic 
medium. A strong acidic medium can cause rapid death of sperm. The activity of 
sperm increases markedly with increasing temperature. Although the sperm can live 
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for many weeks in the suppressed state in the genital ducts of the testes. Life expectancy of ejaculated 
sperm in the female genital tract is only 1 to 2days (24 to 48 hours).   
 
ROLE OF SERTOLI CELLS IN SPERMATOGENESIS:  
Sertoli cells influence spermatogenesis by the following  ways :  
1. Sertoli cells provide nutrition to the developing sperms. 
 2. sertoli cells secrete estrogen, which is essential for spermatogenesis.  
3. sertoli cells secrete hormone binding proteins. These proteins bind with testosterone and 
estrogen and carry the hormones into the fluid of somniferous tubules. 
 4. sertoli cells make these hormones available for the maturation of sperms. 
 
CLOTTING OF SEMEN: 
The clotting enzymes in prostatic secretion cause conversion of fibrinogen into 
coagulum. It is essential for holding the sperms in uterine cervix. 
LYSIS OF COAGULUM: 
The coagulum is dissolved by fibrolysin of the prostate secretion so that the 
sperm become motile. 
SEMEN: 
Semen is a white or grey fluid that contain spermatozoa .It is the collection of 
fluid from testis, seminal vesical, prostate and bulbourethral gland. Semen is 
discharged during sexual act and the process of discharge is called ejaculation. At the 
time of ejaculation, human semen is liquid in nature. Immediately, it coagulates and 
some time it undergoes a secondary liquefaction. 
 
PROPERTIES OF SEMEN: 
1. Specific gravity: 1.028 
2. Volume: 2 to 6ml/ejaculation 
3. Reaction: 
4.Alkaline pH of 7.5.the alkalinity is due to the secretions from prostate. 
COMPOSITION OF SEMEN: 
Semen contains 
1. Sperms : 10% 
2. Products fromseminalvesicle : 60% 
3. Products fromprostate gland : 30% 
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SPERM: 
The total count of sperm is about 100 to 150 million /ml of semen. Male sterility 
occurs, when the sperm count is less than 20 million/ml. After ejaculation of sperm, 
the survival time is only about 24 to 48 hours at a temperature equivalent to body 
temperature. The rate of motility of sperm in female genital tract is about 
3mm/minute. The sperm reach the fallopian tube in about 30 to 60 minute after sexual 
intercourse. The Uterine contraction during sexual act facilitates the movement of 
sperms. 
 
 
CAPITATION OF THE SPERMATION: 
Mature sperm, even when they are coming out of the male genital tract are 
incapable of fertilizing the ovum unless the further changes or capitation takes place 
for a variable period 1 to 10 hours in the female genital tract. The membrane of the 
sperm thus become progressively permeable to calcium ion that enters in abundance 
to initiate the powerful whiplash forward movement of the flagellum or tail instead of 
its previous undulating motion. Calcium has a further role to bring about further 
chance in the acrosome intracellular membrane for helping to releasing its enzyme 
very rapidly in female genitaltract. 
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THE ACROSOMEREACTION: 
The lytic enzyme involved in the sperm penetration is mostly located in the 
anterior sperm head, whereas other such as acrosin are primary contained within the 
acrosome. The anterior surface of the head needs to be removed allowing liberation of 
acrosin before the sperm can be penetrating zona pellucida. Removal of this anterior 
surface of the head is the process called acrosome reaction. 
MECHANISM OF ERECTION: 
The male erectile response is a vascular event initiated by neuronal action and 
maintained by a complex interplay between vascular and neurological, and perhaps 
humoral phenomenons resulting in cascade of events. Erection of penis in simple 
terms consists of trapping pressurised blood within the confines of a limited space 
provided by the spongy corpora cavernosa. This blood – filled spaces relax and open 
up, allowing free inflow of blood leading to expansion of the chambers pulling the 
tunica albuginea tight. The tensed tunica albuginea makes the corpora hard (resistant 
to indentation) and rigid (resistant to flexion). Secondarily, it pinches off the veins 
(that normally let blood leave the chambers) trapping blood inside and contributing to 
the state of engorgement .The valves (actually flaps), according to some experts) that 
control the flow of blood, however are opened and closed by nerves that run through 
the spinal cord to the brain. Activation by the nervous system causes a rapid increase 
in the blood flow into the penis. During erection, as blood flows into the penis, the 
holes in the spongy tissue in the penis get filled in with it. At the same time, flaps in 
the veins leading out of the penis enlarge, cutting off the outflow. Thus, more blood 
flows in than out, and the penis are compressed from the increased pressure from the 
erection itself. In addition, the heart rate and blood pressure increase the pressure of 
blood into the penis increases to maintain its hardness. 
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MECHANISM OF EJACULATION: 
 
The emission phase is the first phase. It involves deposition of seminal fluid 
from the ampullary vas deferens, seminal vesicles and prostate gland into posterior 
urethra. The second phase is the expulsion phase. It involves closure of bladder neck 
followed by the rhythmic contractions of the urethra by pelvicperineal and 
bulbospongiosus muscle, and intermittent relaxation of external urethra sphincters. It 
is believed that the neurotransmitter serotonin (5HT) plays a central role in 
modulating ejaculation. Several animal studies have demonstrated its inhibitory effect 
on ejaculation. Therefore, it is perceived that low level of serotonin in the synaptic 
cleft in these specific areas in the brain could cause premature ejaculation. This theory 
is further supported by the proven effectiveness of selective serotonin reuptake 
inhibitors (SSRIs), which increase serotonin level in the synapse, in treating PE. 
Sympathatic motor neurons control. The emission phase of ejaculation reflex and 
expulsion phase is executed by somatic and autonomic motor neurons. These motor 
neurons are located in the thoraco lumbar and lumbo sacral spinal cord and are 
activated in a coordinated manner when sufficient sensory in a coordinated manner 
when sufficient sensory input to reach the ejaculatory threshold has entered the central 
nervous system. Several areas in the brain, and especially the nucleus 
paragigantocellularis, have been identified to be involved in ejaculatorycontrol. 
 
 
MALE SEXUAL HORMONE: 
The testes secrete the male sex hormones are called the androgens. The 
testicular Androgens are: 
1. Testosterone 
2. Dihydrotestosterone 
3. Androstenedione 
SOURCE OF SECRETION OF ANDROGENS: 
The androgens are secreted in large quantities by testes and in small quantities 
by adrenal cortex. 
TESTES: 
In testes, the androgens are secreted by the interstitial cells of leydig. This 
forms 20% of mass of adult testis, leydig cells are numerous in newborn male infant 
and in adult male after puberty. 
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ADRENAL CORTEX: 
Zona reticularis of adrenal cortex also secretes androgens called testosterone, 
androstenedione and dehydro-epiandrosterone. 
FUNCTION OF TESTOSTERONE: 
In general, testosterone is responsible for the distinguishing characters of 
masculine body. In the fetal life, the tests are stimulated by human chorionic 
gonadotropins secreted by placenta. 
SEX DIFFERENTIATION IN FETUS: 
Testosterone is responsible for the sex differentiation. 
Mullerian Duct 
From this duct, female accessory sex organs like vagina, uterus and fallopian 
tube are developed. 
Wolffian Duct 
From this, male accessory sex organs like epididymis, vas deferens and 
seminal vesicles are developed. 
.DESCENT OF TESTES: 
Initially, testes are developed in the abdominal cavity and are later pushed into 
the scrotum through inguinal canal just before birth. This is called the descent of 
testes. Testosterone is necessary for this. If a male child is born with undecended 
testes, the condition is called „cryptorchidism‟ . 
 
FUNCTION OF TESTOSTERONE IN ADULT LIFE: 
Testosterone has two important functions in adult, 
i. Effect on sexorgans 
ii. Effect on secondary sexualcharacters 
ON SEX ORGANS: 
Testosterone increases the size of penis, scrotum and the testes after puberty. 
ON SECONDARY SEXUAL CHARACTERS: 
Testosterone causes development of secondary sexual characters at puberty, 
which distinguishes the male from female. The secondary sexual characters developed 
by testosterone are as follows: 
MUSCULAR GROWTH: 
One of the most important male sexual characters is the development of 
musculature after puberty. The mass of the muscle increases by about 50% is due to 
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the anabolic activity of testosterone on proteins. 
 
 
BONE GROWTH: 
After puberty the bones grow in thickness with deposition of calcium. The 
increase in thickness is due to increase in total content of bone matrix which is 
because of protein anabolic activity of testosterone. Testosterone causes broadening 
of shoulders and it has a specific effect on pelvis which resultsin, 
a) Narrowing of pelvicoutlet 
b) Lengthening ofpelvis 
c) The funnel like shape ofpelvis 
Pelvis in males is different from that of females, which is broad and ovoid in shape. 
Testosterone also causes early fusion of epiphyses of long bones with shaft. 
CHANGES IN SKIN: 
Testosterone increases the thickness of skin over the entire body surface and 
the ruggedness of subcutaneous tissue. These changes in skin are due to deposition of 
proteins in skin. 
HAIR DISTRIBUTION: 
The testosterone causes male type of distribution of hair on the body. i.e. hair 
growth over the pubis, along linea alba up to umbilicus, on face, on chest and other 
parts of the body like back, in males, the pubic hair has the base of the triangle 
downwards. 
CHANGE IN VOICE: 
At puberty, testosterone causes hypertrophy of laryngeal muscles, the 
enlargement of larynx and lengthening and thickening of vocal cords. 
BASAL METABOLIC RATE: 
At the time of adolescence and earlier part of adult life, thetestosterone 
increases the BMR rises 5 – 10%. This is mostly due to anabolic effects of 
testosterone on proteinmetabolism. 
ELECTROLYTE AND WATER BALANCE: 
Testosterone increases the retention of sodium by reabsorption in renal 
tubules. The action is very mild. 
BLOOD: 
After puberty, testosterone causes slight increase in blood volume by 
increasing water content and by increasing the number of RBCs. 
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CONTROL OF MALE SEXUAL FUNCTIONS BY HORMONES 
A major share of the control of sexual functions in both male and female 
begins with secretion of gonadotropin releasing hormone (GnRH) by the 
hypothalamus. This hormone in turn stimulates the anterior pituitary gland to secrete 
two other hormones called the gonadotropic hormones. 
1. Luteinizing hormone (LH) – This hormone is essential for the secretion of 
testosterone from leydigcells. 
2. Follicle stimulating hormone (FSH) – it accelerates the process of spermatogenesis, 
Combination withtestosterone. 
NEGATIVE FEEDBACK CONTROL OF TESTOSTERONE: 
Testosterone regulates its own secretion by negative feedback mechanism. It 
acts on hypothalamus and inhibits the secretion of LHRH. When LHRH secretion is 
inhibited, LH is not released from anterior pituitary resulting in stoppage of 
testosterone secretion from testes. On the other hand, when testosterone production is 
low, lack of inhibition of hypothalamus leads to secretion of testosterone through 
LHRH and LH. 
 
ABNORMALITIES OF SEXUAL FUNCTION: 
ENLARGEMENT OF PROSTATEGLAND: 
Enlargement of prostate gland occurs dueto: 
1. Hyperplasia of glandular structures and connectivity tissues benign 
(non-malignant)enlargement 
2. Cancer – malignant enlargement 
 
 
HYPOGONADISM IN MALES: 
Hypogonadism is a condition characterized by reduction of functional activity 
of gonads. 
SIGNS AND SYMPTOMS: 
The clinical picture of male hypogonadism depends upon whether the 
testicular deficiency develops before or afterpuberty. 
BEFORE PUBERTY: 
The symptoms of hypogonadism are similar to those developed due to 
extirpation of testes before puberty. 
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AFTER PUBERTY: 
The symptoms are similar to those developed due to removal of testes after 
puberty. 
IN ADULT: 
Hypogonadism caused by testicular disorder increases the gonadotropin 
Secretion and the condition called hypergonadotropic hypogonadism. Hypogonadism 
that occurs due to deficiency gonadotropin is called hypogonadotropic hypogonadism. 
FROHLICHS SYNDROME: 
It is the disorder characterized by obesity and hypogonadism in adolescent boy 
also called adiposo genital syndrome or hypothalamic eunuchism. 
EFFECT OF TEMPERATURE ON SPERMATOGENESIS: 
Increasing the temperature of the testes can prevent spermatogenesis by 
causing degeneration of most cells of the seminiferous tubules besides the 
spermatogonia. It has often be stated that the reason, the testes are located in the 
dangling scrotum is to maintain the temperature of these glands, below the internal 
temperature of the body, although usually only about 2º C below the internal 
temperature. On cold days scrotal reflexes cause the musculature of the scrotum to 
contract, pulling the testes close to the body to maintain this 2º C differential. Thus 
the scrotum theoretically acts as a cooling mechanism for thetestes. 
CRYPTORCHIDISM: 
Cryptorchidism means failure of the testis to descent from the abdomen in to 
the scrotum at or near the time of birth of a fetus. During development of the male 
fetus, the testes are derived from the genital ridges in the abdomen. A testis that 
remains throughout the life in the abdominal cavity is incapable of forming sperm. 
The tubular epithelium undergoes degeneration, leaving only the interstitial structures 
of thetestis. 
SEMEN ANALYSIS: 
COLLECTION: 
The semen specimen should be collected in a small clean wide mouthed jar of 
10 to 20 ml (using larger jar may cause drying of some portion, when it is transported 
to the laboratory). The container must be spotlessly clean. Masturbation (self- 
stimulation) is the most preferred method. Coitus interrupts (withdrawal of penis just 
prior to ejaculation during sexual intercourse) may be used, but there is always a 
possibility of loss of the sperm rich initial portion. The container must be ideally 
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warmed to the body temperature, as sperms are especially susceptible to cold. The 
slide must be warmed, as otherwise motility studies may show erroneous result. 
Masturbation can be very stressful for some men especially when they know their 
counts are low, or if they have had problems with masturbation on demand for semen 
analysis in the past. The condition of the toilet room, where the patient has to go for 
procuring the specimen, is often related to their not providing the proper specimen. 
Men failing to provide a specimen could be advised either to have female partners 
beside or to see sexually arousing pictures for helping them to provide sample. They 
can also use a mechanical vibrator to get an erection. In some cases, additional 
assistance by using liquid paraffin helps in masturbation. The infertility centres should 
have a special private room to allow the patients for the masturbation on demand. The 
semen samples must be collected after a sexual abstinence 3 to 5 days, or at least 72 
hours after the last ejaculation (no sex or masturbation). It is very important to keep 
with the chosen abstinence schedule, because variations in the time period between 
ejaculations interfere with the accuracy of test results. For up to one week, semen 
characteristics, such as volume and sperm concentration, may increase with each day 
of abstinence; but after that period, the sperm motility is usually impaired. 
COMPONENTS OF SEMEN ANALYSIS: 
Sperm count 
Motility 
Morphology 
Volume 
Fructose level 
 
SPERM COUNT: 
Sperm count, or sperm concentration to avoid mix-up, measures the 
concentration of sperm in a man's ejaculate, distinguished from total sperm count, 
which is the sperm count multiplied with volume. Anything over 20 million sperm per 
milliliter is considered normal. Anything less is considered „oligospermia‟ . The 
average sperm count today is around 60 million per milliliter in the Western world, 
having decreased by 1-2% per year from substantially higher number decades ago. 
 
 
 
pH 
51  
MOTILITY: 
A more specified measure is motility grade, where the motility of sperm is 
divided into four different grades: 
 
Grade 4: Sperm with progressive motility. These are the strongest and swim fast in 
a straight line. Sometimes it is also denoted motility a. 
Grade 3: (non-linear motility): These also move forward but tend to travel in a 
curved or crooked motion. Sometimes also denoted motility b. 
Grade 2: These have non-progressive motility because they do not move forward 
despite the fact that they move their tails. 
Grade 1: These are immotile and fail to move at all. 
MORPHOLOGY: 
i. Head - The head should be oval andsmooth. 
ii. Mid piece - the mid piece should be straight and slightly thicker than the 
tail. 
iii. Tail - the tail should be single, unbroken, straight and withoutcoils. 
VOLUME: 
The volume of the sample is measured between 1.0 mL and 6.5 mL is normal; 
WHO criteria specify that any volume greater than 2.0 mL is normal. Low volume 
may indicate partial or complete blockage of the seminal vesicles, or that the man was 
born without seminal vesicles. In clinical practice, a volume of less than 2 mL in the 
setting of infertility and absent sperm should prompt an evaluation for obstructive 
azoospermia. 
FRUCTOSE LEVEL: 
The normal level of fructose in the semen is at least 3 mg/ml. WHO specify a 
normal level of 13 μmol per sample. Absence of fructose may indicate a problem with 
the seminal vesicles. 
pH: 
The normal range of pH of the sample is 7.1-8.0; WHO criteria specify normal 
as 7.2-7.8. Acidic ejaculate (lower pH value) may indicate one or both of the seminal 
vesicles are blocked. A basic ejaculate (higher pH value) may indicate an infection. A 
pH value outside of the normal range is harmful to sperm. 
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LIQUEFACTION: 
The liquefaction is the process when the gel formed by proteins from the 
seminal vesicles is broken up and the semen becomes more liquid. It normally takes 
less than 20 minutes for the sample to change from a thick gel into a liquid. An 
abnormally long liquefaction (more than 30 minutes) time may indicate an infection. 
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TOTAL MOTILE SPERMATOZOA: 
Total motile spermatozoa (TMS) or total motile sperm count (TMSC) is a 
combination of sperm count, motility and volume, measuring how many million 
sperm cells in an entire ejaculate is motile. Use of approximately 20 million grade  
3+4 sperm in ICI, and 5 million ones in IUI may be an approximate recommendation. 
OTHERS: 
The sample is tested for white blood cells. A high level of white blood cells 
(over 1 million per milliliter) may indicate an infection. 
ABNORMALITIES: 
i. Aspermia: absence ofsemen 
ii. Azoospermia: absence of sperm 
iii. Oligospermia: low number ofsperm 
iv. Asthenozoospermia: poor sperm motility 
v. Teratozoospermia: sperm carry more morphological defects thanusual[68]. 
ADVANCED SPERM FERTILITY TESTES: 
COMPUTER-ASSISTED SEMEN ANALYSIS (CASA) 
The new technologies such as CASA incorporate the video systems to  
measure the types and the speed of sperm motility. Normal sperms swim faster and 
straighter than the abnormal ones. The average speed of a human sperm is roughly 48 
to 96 mm per second. CASA permits the measurement of additional motility 
parameters such a curvilinear velocity (VCL), straight-line velocity (VSL), linearity, 
and flagellar beat frequency. CASA Measures the parameters such as VCL, VSL and 
amplitude of lateral head (ALH). The quality of sperm movement is based on a 
classification system of 0 to 4, wherein 0 represents no movement and 4 represents 
excellent forward progression; for example, a semen sample with 60% motility would 
be characterized as 3+ to4.2. 
QUALITY ASSESSMENT OF CASA: 
Three levels of quality assessment are generally accepted: structure, process 
and results. 
SPERM CLUMPING OR AGGLUTINATION: 
The sperms may clump head-to-head, tail-to-tail, or head-to-tail. In particular 
tail-to-tail agglutination of motile sperm is noteworthy and usually is followed up 
with SpermFunction. 
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SEMEN CULTURE TEST: 
In a semen culture test, the semen sample is tested for the presence of bacteria. 
Testing the bacterial sensitivity to antibiotics is mandatory if there is any presence of 
bacteria. Whether the bacteria present in the specimen is that are usually seen in 
normal semen or those of a bacterial disease, without the evidence of inflammation or 
infection, there is no indication for routine culture or antibiotic treatment in infertile 
men. If urine analysis is abnormal or bacterial prostatitis is suspected from the history 
or the physical examination, semen culture is certainly indicated. The common 
sexually transmitted organisms such as Chlamydia trachomatis, Mycoplasma hominus 
and Ureaplasma urealyticulum have been implicated in reproductive failure in animals 
and humans. 
BIOCHEMICAL TESTS: 
Biochemical analysis of seminal plasma mostly provides insights into the 
function of the accessory sex glands. The fructose content of semen (normal value - 
250-400 mgm or 4-28 mmol/litre) should be routinely tested. Low fructose content 
(less than120 mgm) is often due to seminal vesiculitis, androgen deficiency or partial 
ejaculatory duct obstruction. Its absence indicates complete obstruction either due to a 
congenital block at the level of ejaculatory duct or proximal to it like agenesis of the 
vas and the seminal vesicle or following acquired post-infective cicatrisation. Almost 
invariably, these conditions are associated with azoospermia or severe oligospermia. 
The epididymis is represented by glyceryphosphorylcholine (GPC), the seminal 
vesicles by fructose, and the prostate gland by zinc. 
 
IMMUNOLOGICAL TESTS: 
In the enzyme-linked immune sorbent assay (ELISA) test, the antisperm 
antibodies measuring up to 20 units/m in 32 or 64 dilutions is considered normal. 
SPERM FUNCTION TESTS: 
Thespermfunctiontestsassessthesperm‟ sabilitytofertilizetheovum.There is a 
drawback that these tests are often not standardizedadequately. 
SPERM VIABILITY OR SPERM SURVIVAL TEST: 
The sperm viability may be determined by two methods-Eosin Y stain 
exclusion and hypo-osmotic swelling or HOS assay. 
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BOVINE CERVICAL MUCUS TEST: 
The bovine cervical mucus test is another form of testing for the ability of the 
sperms to penetrate and swim through cervical mucus. These tests to assess 
thefertilizing potential of sperms. This in vitro functional test measures the ability of 
penetration of the sperms. The end point of this assay is penetration of the ovum and 
decondensation of sperm heads. Men with sperm of low SPA score are less likely to 
achieve a spontaneous pregnancy than those with high SPA score. 
SPERM CHROMATIN STRUCTURAL ASSAY (SCSA): 
To measure the level of DNA fragmentation in the sperm is to help the 
diagnosis and treatment for male infertility. The sperm with high levels of DNA 
fragmentation have a lower probability of producing a successful pregnancy. Vitamin 
C protects the sperms from endogenous oxidative DNA damage that could affect 
sperm quality and increased risk of genetic defects, particularly in population with 
low ascorbic acid like smokers against free radical damages. 24 Studies show that a 
daily dose of 1000 mg showed statistically significant improvement ofsperms. 
THE POSTCOITAL TEST(PCT): 
It is first performed by Sims, has traditionally been a common way to 
determine cervical mucus/sperm interaction. This test evaluates sperm concentration 
and motility in an aspirate of cervical mucus at midcycle shortly after the couple has 
intercourse. Results of a normal PCT would show the presence of 20 or more 
spermatozoa per high-power field. An abnormal PCT results most commonly is 
secondary to inappropriate timing of coitus. Other causes include ASA, an ovulation, 
an abnormal hormonal milieu, female or male genital tract infections, poor semen 
quality, and male sexualdysfunction. 
Sperm Penetration Assay (Spa): 
The SPA was developed to measure the functional properties of sperm and 
was initially developed following the observation that, upon the removal of the zona 
pellucida of hamster ova, the species specificity of fertilization and the block to 
polyspermy are lost. In particular, heterologous penetrations between hamster ova and 
sperm from a variety of species, including humans, has been observed. Ideally, human 
ova should be used for this assay, but they are not widely available, and there are 
ethical problems associated with their use. Therefore, hamster ova have provided a 
useful model for the measurement of human sperm function. For fertilization to occur 
in vivo, the sperm must first be capacitated and have undergone the acrosome 
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reaction. The physiology of sperm capacitation is not clearly defined. In particular, it 
is not known whether capacitated sperm that have gained the ability to penetrate 
humanovahaveundergonetheacrosomereaction,orwhetherthisoccursasalocal 
event at the time of gamete fusion. The use of SPA as a measure of potential fertility 
is based on the theory that fertile sperm samples will either penetrate most hamster 
ova or result in a significant amount of polyspermy of the penetrated ova. Infertile 
sperm samples are expected to penetrate a lower percentage of ova or result in a lesser 
degree of polyspermy. Consideration should be given to obtaining the SPA in couples 
with unexplained infertility or in couples in whom the decision is being made to 
precede with intrauterine insemination (IUI) or IVF, since lower SPA results have 
been predictive of poor success with IVF and lower pregnancy rates in couples 
attempting conception throughintercourse. 
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REACTIVE OXYGEN SPECIES (ROS) ASSAY: 
For cells living under aerobic conditions, oxygen represents a paradox: While 
it is required for survival and normal function, its metabolites can be potentially toxic 
due to the generation of oxygen-free radicals. Some of these metabolites, called ROS, 
have been shown to be produced by spermatozoa and to generate toxic effects on 
sperm function. However, when produced at the right time and amount, these ROS 
can also initiate and promote normal physiologic reactions such as sperm 
hyperactivation and capacitation. In human semen, high ROS formation was detected 
in 40% of semen samples from an unselected population of men consulting an 
infertilityclinic. 
NUTRITION: 
ZINC: 
Zinc is the most important nutrient mineral influencing male fertility. Zinc 
level in the seminal plasma is directly related to sperm motility. Dietary zinc 
restriction reduces both sperm count and seminal plasma volume. Zinc levels in 
seminal plasma of normal, oligospermic, asthenospermic and azoospermic subjects 
show that a linear direct relationship seems to exist between zinc in seminal plasma 
and motility of spermatozoa. Dietary restriction of zinc can affect testicular function 
adversely. The serum testosterone concentration and seminal volume are most 
sensitive to zinc depletion in men in the reproductive period. 
VITAMIN B 12: 
Vitamin B 12 deficiency also plays a role in fertility. “Intrinsic factor” is 
necessary for the proper absorption of B12 and its deficiency is one of the causes of 
secondary infertility in male. 
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VITAMIN C: 
Studies have shown the concentration of ascorbic acid in seminal plasma 
directly reflects dietary intake, and lower levels of vitamin C may lead to infertility 
andincreaseddamagetothesperm‟ sgeneticmaterial.36Fragaetaldemonstratedthis by 
reducing ascorbic acid intake in healthy men from 250 mg to 5 mg per day. Seminal 
plasma levels of vitamin C decreased by 50 percent, with a concomitant 91- percent 
increase in sperm with DNAdamage. 
L-ARGININE: 
The biochemical and physiological relevance of L-arginine lies in its role as 
the precursor in the synthesis of polyamines and testosterone. The polyamines 
putrescence and spermidine are organic components important to sperm motility. An 
arginine metabolism is a factor in normal sperm production being involved as a  
source of nitric oxide within spermatozoa. Nitric oxide (at endogenous 
concentrations) appears to be necessary for adequate sperm motility. The endothelial 
(eNOS) and brain (b NOS) nitric oxide syntheses are abundant in normozoospermic 
samples but is low in asthenozoospermic patients. Consequently, an adequate dietary 
amount of Larginine is necessary for normal spermatogenesis, especially for the 
sperm motility and arginine aspartate (9 g daily) has been found to be effective in 
some cases of asthenospermia. Larginine, 4 gm. daily has been shown to improve 
sperm counts in men with oligospermia. Nuts, oilseeds, flesh foods, pulses and 
legumes are common sources ofL-arginine. 
VITAMIN E: 
The membranes of the germ cells and spermatozoa are very sensitive to 
oxidation because of their high content of PUFA (Polyunsaturated fatty 
acids).Vitamin E is a major lipophilic chain-breaking anti-oxidant, which protects 
tissue PUFA against peroxidation, a property that is beneficial in the male 
reproductive physiology. Oral78 administration of vitamin E significantly improves 
the in vitro function of human spermatozoa as assessed by the zona binding test. 
Vitamin E antioxidant therapy is however, dependent on the dosage or the in vitro 
concentration of the vitamin. Vitamin E in a dose of 200 IU twice daily acts an 
antioxidant and improves sperms‟  ability toimpregnate. 
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SELENIUM: 
Men with reduced sperm motility, supplementation with selenium (100 mcg 
per day for three months) significantly increased sperm motility, but it had no effect 
on sperm count. Selenium is one of the important ingredients that is very often 
lacking in order mean and can be found in horsetail, which has been used with success 
in ED following prostaticenlargement. 
L- Carnitine: 
Sperm motility also increased both in quantitative and qualitative manners. In a 
multicentric study, increase in the sperm motility was also observed in terms of both 
rapid linear progression and linearity index along with that the sperm output after oral 
administration of L -carnitine in patients with idiopathic asthenozoospermias. Two 
amino acids Iysine and methionine that is necessary for the biosynthesis of L-carnitine 
in the body. 
ANTIOXIDANTS: 
Polyunsaturated fatty acids and phospholipids are key constituents in the 
sperm cell membrane and are highly susceptible to oxidative damage. Sperm produce 
controlled concentrations of reactive oxygen species, such as the superoxide anion, 
hydrogen peroxide, and nitric oxide, which are needed for fertilization; however, high 
concentrations of these free radicals can directly damage sperm cells. Disruption of 
this delicate balance has been proposed as one of the possible etiologies of idiopathic 
male infertility. About someAnti-oxidants, 
Vitamin A alone improved sperm function and IVF rates in studies. 
Vitamin A, Vitamin E, and essential fatty acids (omega-3 fats) were shown 
to increase sperm count in another study. 
Folic acid and zinc may increase sperm concentration. 
The bottom line: having a healthy diet is important for male fertility. You 
should have a diet rich in a variety fruits and vegetables and take a good 
quality multivitamin daily. You may also consider taking an omega-3 
supplement, if your intake of fish is low. 
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COENZYME Q-10: 
In sperm cells, coenzyme Q10 (CoQ10) is concentrated in the mitochondrial 
midpiece, where it is involved in energy production. It also functions as an 
antioxidant, preventing lipid peroxidation of sperm membranes. When sperm samples 
from 22 asthenospermic men were incubated in vitro with 50 micro CoQ10, 
significant increases in motility were observed. CoQ10 (60 mg) was given to 17 
infertile patients for a mean 103 days, and although there were no significant changes 
in standard sperm parameters, there was a significant improvement in fertilizationrate 
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TRIAL DRUG 
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LITERATURE REVIEW OF TRIAL DRUG: 
PREPARATION AND PROPERTIES OF TRIAL DRUG: 
 
DRUGNAME : THETRAN ILAGAM 
                      TEXT REFERENCE      : Anuboga vaithya navanetham (part-8), Page no: 143 
INGREDIENTS: 
1. Thetrankottai (Strychnos potatorum) - 70 gms 
2. Narseeragam  (Cuminum cyminum) - 35 gms 
3. Kasakasaa (Papaver somniferum )  - 17.5 gms 
 
4. Lavangapattai ( Cinnamomum verum) - 5.2gms 
5. Vaalmelagu (Piper cubeba)   - 5.2gms 
6. Sapjavithai Ocimum basilicum(seeds) - 5.2gms 
 
7. Saathikkaai (Myristica fragrans)    Each one 
8. Saathipathri(Myristica fragrans) 
9. Melagu (Piper nigrum) 
10. Esappukool vithai (Plantago ovate)   (10.5gram) 
11. Poonaikan kungiliyam Pistacia lentiscus 
12. Madhulai vithai(Punica granatum ) 
13. Neermulli vithai(Hygrophila auriculata) 
14. Seemai thanneervittankizhangu - Asparagus racemosus  -   35 gm 
15. Nilappanai kizhangu(Curculigo orchioides)          -35 gm 
16. Omam(Trachyspermum ammi)                            -17.5 gm 
17. Thiratchai pazham(Seeds removed)-Vitis vinifera           -26 ¼ gm 
18. Perichchan pazham(Seeds removed)- Phoenix dactylifera   - 43 ¾ gm 
19. Saarap paruppu -Buchanania Lanzan    -35 gm 
20. Padham paruppu -Prunus dulcis                                      -280 gm 
21. Nattu Sarkkarai   -Jaggery                     -350 gm 
22. Karkandu  -Rock candy                175 gm 
23. Nei               -Ghee                               -175 gm 
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METHOD OF PREPERATION: 
 All the above mentioned ingredients are purified as per the text of  chikitcha rathna theepam 
raw drug no 17 and 18 made  paste with using milk, Other raw drugs after purification make a fine  
powder and choorana suththi with the use of milk. And make paagu ,mixture with choornam then  
Ghee added  medicine prepared stored in an air tight Glass container.  
 
Standard Operating Procedure 
Source of raw drugs: 
            The required raw drugs for the trial medicineswas  purchased from a well reputed raw  
drug shop andthe raw drugs would authenticated by Assistant Professor Medicinal Botany 
 and Gunapadam HOD . After that the raw drugs would  purified as per siddha literatures  
in the presence of faculty members, then the trial drugs were prepared in the Gunapadam  
laboratory of National Institute of Siddha by following Standard operating Procedures. 
 
PURIFICATION METHOD: 
Thetran kottai: 
Soak   in  butter  milk  for  a  period  of 1 saamam (3 hours)  then  allow  it  to  dry 
Narseeragam: 
 Cleaned & remove dust Dried  in sunlight  shadow  and  fried. 
Kasakasaa: 
   Cleaned & remove dust Dried  in sunlight  shadow  and  fried. 
Lavangapattai: 
Dried  in sun light shadow and fried. 
Vaalmilagu: 
 Removed stem and dried in sun shadow . 
Sathikkai: 
 Remove the outer cover, cut into small pieces and dry it in sun shadow. 
Elavanga pathiri: 
Dried  in sun shadow  and fried 
Sapjavithai: 
Cleaned & remove dust Dried  in sunlight  shadow  and  fried. 
Esappukol vithai: 
Cleaned & remove dust Dried  in sunlight  shadow  and  fried. 
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Neermulli vithai: 
Dried  in sun shadow  and fried 
Milagu: 
 Soak   in  butter  milk  for  a  period  of 1 saamam (3 hours)  then  allow  it  to  dry. 
Maathulai vithai: 
 Dried  in sun shadow  and fried. 
Poonaikan kungiliyam: 
 Boiled in Tender coconut water and dry. 
Saathipthri: 
 Clean with cloth remove any decay part. 
Saalaamisiri: 
 Dried  in sun shadow  and fried. 
Omam : 
 Drenched in limestone water and dried. 
Seemai thanneervittan kizhangu : 
 Dry and make fine powder and pittaviyal boiled 1 samamam (3 hours) then sun shadow . 
Nilampanai kizhangu: 
 Dry and make fine powder and pittaviyal boiled 1 samamam (3 hours) then sun shadow . 
Saarapparu: 
Cleaned & remove outer skin Dried  in sunlight  shadow  and  fried. 
Bhadham paruppu: 
 Cleaned & remove outer skin Dried  in sunlight  shadow  and  fried. 
Nattu sarkkarai: 
 Grined and saliththal by using muram 
Pericham pazham : 
 Remove the  seed  
 
DISPENSING: 
The Ilagam is given in 70 gram in packets .(5gm after food along with milk twice a day) for 7 
days 
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THETRAN VITHAI 
 
THETRAN VITHAI – Strychnos potatorum 
SUVAI - KAIPPU 
THANMAI -VEPPAM 
PIRIVU -KARPPU 
ACTION -  TONIC ,NUTRITIVE 
GUNAM: 
NARSEERAGAM  – Cuminum cyminum 
SUVAI - INIPPU 
THANMAI -THATPAM 
PIRIVU -INIPPU 
ACTION - Carminative,Stimulant,Stomachic,Astrigent 
GUNAM: 
                                                                                           
KASAKASA    - Papaver somniferum 
SUVAI         - INIPPU 
THANMAI - VEPPAM 
PIRIVU - INIPPU 
ACTION - DEMULCENT,NUTRITIVE,ASTRIGENT 
GUNAM: 
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LAVANGAPATTAI- Cinnamomum verum 
SUVAI - KARPPU ,INIPPU 
THANMAI -THATPAM 
PIRIVU -INIPPU 
ACTION - 
STIMULANT,CARMINATIVE,APHRODISIAC 
GUNAM: 
 
 
        VAALMUZHAGUPiber cubeba 
 
       SUVAI     - KARPPU 
THANMAI -VEPPAM 
PIRIVU -KARPPU 
ACTION - 
STIMULANT,CARMINATIVE,DIURETIC,EXPECTORANT 
GUNAM: 
 
SAPJAVITHAI          - Ocimum basilicum 
       SUVAI -  INIPPU  
THANMAI -THATPAM 
PIRIVU -INIPPU 
ACTION -  DIURETIC,APHRODISIAC 
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GUNAM: 
SAATHIKKAAI       - Myristica fragrans  
 
        SUVAI - THUVARPPU,KAARPPU 
THANMAI -VEPPAM 
PIRIVU -KAARPPU 
ACTION        STIMULANT, CARMINATIVE, NARCOTIC, 
AROMATIC,APHRODISIAC, TONIC 
 
GUNAM: 
 
SAATHIPATHRI -Myristica fragrans  
 
       SUVAI - KAARPPU,THUVARPPU 
THANMAI -VEPPAM 
PIRIVU -KAARPPU 
ACTION - 
APHRODISIAC,STIMULANT,CARMINATIVE 
 
GUNAM: 
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      M ELAGU - Piper nigrum
        SUVAI - KAIPPU,KAARPPU 
THANMAI - VEPPAM 
PIRIVU - KAARPPU 
ACTION - 
ANTIDOTE,ANTIVATHA,RESOLVENT,ACRID 
GUNAM: 
ESAPPUKOOL VITHAI –Plantago ovate 
     SUVAI - --- 
THANMAI - ---- 
PIRIVU - ---- 
ACTION - DEMULCENT,DIURETIC,EMOLLIENT 
PONAIKAN KUNGILIYAM- Pistica lentiscus 
      SUVAI -KAIPPU 
THANMAI - VEPPAM 
PIRIVU - KAARPU 
       ACTION                      - STOMACHIC,ASTRINGENT,REFRIGERANT 
 
 
 
       MADHULAI VITHAI- Punica granatum 
      SUVAI - INIPPU 
THANMAI - THATPAM 
PIRIVU - INIPPU 
ACTION -APHRODISIAC,ASTRIGENT,TOENIFUE 
GUNAM: 
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         NEERMULLI- Hygrophila auriculata 
     SUVAI - INIPPU,SIRUKAIPPU 
THANMAI - THATPAM 
PIRIVU - INIPPU 
ACTION -APHRODISIAC,DIURETIC 
GUNAM: 
         THANNEERVITTAN KIZHANGU-Asparagus racemosus 
       SUVAI - INIPPU, 
THANMAI - THATPAM 
PIRIVU - INIPPU 
ACTION -
APHRODISIAC,NUTRITIVE,ANTISPASMODIC 
GUNAM: 
NILAPPANAI KIZHANGU-Curculigo orchiodes 
       SUVAI - INIPPU, 
THANMAI - THATPAM 
PIRIVU - INIPPU 
ACTION -
TONIC,DIURETIC,ASTRIGENT,EMOLIENT 
GUNAM: 
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        OMAM-Trachyspermum ammi 
       SUVAI - KARPPU,SIRUKAPPU 
THANMAI - VEPPAM 
PIRIVU - KAARPPU 
ACTION -HYPNOTIC, SEDATIVE,MILD 
DIURETIC 
GUNAM: 
THIRATCHAI PAZHAM -Vitis vinifera 
        SUVAI -INIPPU 
THANMAI -THATPAM 
PIRIVU - INIPPU 
ACTION -LAXATIVE,DIURETIC,NUTRITIVE 
PERICHCHAN PAZHAM-Phoenix dactylifera 
       SUVAI - INIPPU 
THANMAI - THATPAM 
PIRIVU - KARPPU 
ACTION -TONIC,NUTRITIVE,LAXATIVE, 
GUNAM: 
        SARAPARUPPU-Buchanania lanzan 
       SUVAI - INIPPU 
THANMAI - THATPAM 
PIRIVU - INIPPU 
ACTION -APHRODISIAC 
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GUNAM: 
 
         PADHAM PARUPPU-Prunus dulcis 
        SUVAI - INIPPU 
THANMAI - THATPAM 
PIRIVU - INIPPU 
ACTION -APHRODISIAC 
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INGREDIENTS OF TRAIL DRUG 
 
 
     
 
 
 
 
KASAKASA 
   NARSEERAGAM                 THETRANKOTTAI 
LAVANGAPATTAI 
PONAIKANKUNGIL
IYAM   
SAARAPARUPPU 
 
SATHIKAI 
KUNGILIAM 
ELAVANGAPATTAI 
S U  
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THANNERVITTAN PERITCHAM                                                                                            
PADAHAM PARUPPU 
 
NILAPPANAI                OMAM       THIRATCHAI 
  VAALMILAGU 
   
MADHULAISEED 
      DDD     
SAPJAVITHAI 
NEERMULLI VITHAI
  
           MMIILAGU SAATHIPATHRI 
VALMELGU KARUNCHEERAGAM NEERMULLI 
T IVITHAI MATHULAIVITHAI SATHIPATHRI 
NIL P NAI  ULAR THIRATCHAI 
SADHAVARI PERACHAMPALAM BADAM PARUPU 
MILAGU 
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THETRAN ILAGAM 
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\ 
MATERIALS AND METHODS 
STUDY DESIGN: 
Preclinical and Comparative  Clinical trial ofAAN MALADU (Male 
Infertility)was conducted at the OPD section of, SIRAPPU MARUTHUVAM 
DEPARTMENT attached to AYOTHIDASS PANDITHAR HOSPITAL, Chennai-
47, during the 
period of 2015-2018 
The study was approved by Institutional Ethics Committee and the IEC 
approval no. NIS/IEC/2016/11-13/ 14.10.2016  and the study was registered in CTRI 
and the registered no.REF/2018/03/018682 
POPULATION AND SAMPLE: 
The population consists of all patients satisfying the inclusion and exclusion 
criteria mentioned below. Sample consists of Aan maladu patients attending the OPD 
section of Sirappu Maruthuvam Department attached to Ayothidass pandithar 
Hospital, Chennai-47. 
SAMPLE SIZE: 
The trial size was  40 patients. 
(Group –I   :   20 patients Internal Medicine only) 
(Group – II   :  20 patients  Internal  Medicine along with Yogam therapy) 
 
SUBJECT SELECTION: 
         Patients reporting with symptoms of inclusion criteria was  subjected to screening 
test and documentation 
INCLUSION CRITERIA: 
 
 
 Male who doesn’t have chance of conception for 1 year after Marriage with frequent 
unprotected sexual intercourse. 
 Age :24-50yrs 
 Sperm count ≤20 million/ml 
 Motility ≤50% 
 Patients with classical features of    The W.H.O. criteria (1992) for semenogram.   
 Patient willing to undergo Semen analysis &Routine blood investigation before and 
after treatment 
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 Willing to participate in trial and signing consent by fulfilling the condition of proforma. 
EXCLUSION CRITERIA: 
 Azoospermia 
 Teratospermia 
 Hydrocele 
 Varicocele 
 Diabetesmellitus 
 Hypertension 
 Cardiacdisease 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of any serious adverse effect during drug trial. 
 Poor patient compliance & defaulters 
 Patient unwilling to continue the course of clinical Study. 
 Occurrence of any other systemic illness 
 
DURATION OF TREATMENT: 
 
45 days. 
 
         Herbal Drug Authentication :Certificate No:NISMB2932017 
 
 
TESTS AND ASSESSMENTS: 
I. Clinical assessment  
II. Siddha system assessment 
III. Routine investigations 
I.CLINICAL ASSESSMENT:The initial assessment was done before the treatment . The 
assessment of therapy  was made by adopting two parameters.  
  Semen Analysis  
  Sexual Health Scoring   
1.  SEMEN ANALYSIS – As per the recommendations of WHO (1992). [4] Collection of sample 
Masturbation was advised to all patients for method of collection. The sample was collected 
between 9-10 a.m. in case of coitus interrupts and it was delivered to laboratory within 20 
minutes of the collection of semen.   
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2. Examination of Semen 
3. Volume: Sample was measured by calibrated test tube and volume of semen was noted. 
4.   pH: pH was measured by comparing the standards pH paper colour changes  
5. Viscosity: By lifting the glass rod from semen in test tube and on the basis of length of thread 
formation, the viscosity was scored as 0, 1, 2, 3. (4) 
6. Liquefaction time: Liquefaction time (T) = T2 - T1 (T2 = Time observed till semen sample 
liquefies, T1= Time at the semen collection) 
7.   Motility: The spermatozoa were scanned systematically for 4 types of motility i.e. rapidly 
linear progressive, sluggishly linear progressive, nonprogressive and immotile.  
8.  Viability: For counting viable sperms eosin stain was used in laboratory.  
9.  Gradation of Sperm count: 
  Severe Oligozoospermia    < 5 mill / ml. 
 Moderate Oligozoospermia  > 5 and < 20 mill / ml 
  Mild Oligozoospermia       > 20 and < 40 mill / ml Normal     > 40 mill / ml (9) 
10.  Morphological evaluation: Abnormal spermatozoa were counted like total abnormal forms 
and abnormality in head, mid piece, tail and headless spermatozoa.  
 
SEXUAL HEALTH SCORING : 
 The second objective parameter of assessment is sexual health parameters like sexual desire,  
 erection, rigidity and orgasm. The scoring system developed by Mehra and Singh (1995)  
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 Sexual Health Score 
 
 
 
 
 
 
Sexual Desire 
No desire at all 0 
Lack of desire        1 
Desire but no activity       2 
Desire only on demand of the partner   3 
 Normal desire        4 
Excess desire     5 
 
 
 
 
Erection 
 No erection by any methods    0 
 Erection with artificial methods     1 
 Erection but unable to penetrate    2 
 Initial difficulty but able to penetrate     3 
Erection with occasional failure      4 
 Erection when ever desired    5 
 
Rigidity  
 
Unable to maintain erection or unable to continue sexual act                0 
Some case in erection but able to continue   1 
Sexual act to maintain erection and continue sexual act  2 
 
 
 
 
Orgasm  
No ejaculation at all       0 
Lack of enjoyment in most of occasions   1 
Enjoyment in 25% of sexual encounters     2 
Enjoyment in 50% of sexual act     3 
Enjoyment in 75% of sexual act       4 
Enjoyment in every sex act      5 
TOTAL SOCORE=13 
Assessment of To improvement of Sexual quality life by Sex Health Score 
Increased sexual desire, erectile function, ejaculatory function, frequency, duration of coitus, getting 
orgasm or sexual satisfaction 
 
0 - None        0-Nil   
1- Slight        1-1%-9% 
2- Moderate        2- 10%-29% 
3-Good        3-30%-49% 
4-Very good 
5-Excellent                 4-50%-69% 
         5-70%-89% 
         6-90%-100% 
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EVALUATION OF CLINICAL PARAMETERS: 
 
The history includes past, personal, family, occupation, dietary habits, 
seasonal history and associatedhistory. 
Clinical investigation: 
 
Blood: 
Urine: 
TC, DC, ESR, Hb, VDRL, Sugar, Urea, Serum Creatinine, Cholesterol 
Albumin, Sugar, Deposit 
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SEMEN ANALYSIS 
 The volume, colour, appearance of the SEMENsample 
 
 Approximate number of total SPERMCELLS 
 
 SPERM MOTILITY/ FORWARD PROGRESSION 
 
 Percentage of sperm with NORMAL MORPHOLOGY &MOTILITY 
 
 VISCOSITY ofsemen 
 
 pH of the Seminalfluid 
 
 Liquificationtime 
 
 Antispermantibody 
 
 
SIDDHA ASSESSMENT: 
 
 EnvagaiThervugal 
 Neerkuri 
 Neikkuri 
A case sheet format was prepared on the basis of the Siddha 
methodology example envagai thervugal, mukkutram, nilam, kaalam, udal 
thathugal, including neerkuri and neikuri. Individual case sheet was 
maintained for each patient at outpatient department. 
Data collection forms: 
Required information was  collected from each patient by using following 
forms. 
FormI : Screening and selection 
proforma FormII: History 
takingproforma 
Form III : Clinical assessment proforma/Sexual Heaith score Form 
FormIV : Laboratory Investigation 
FormV :  Information sheet 
 FormVI : Drug Compliance form 
FormVII : Consent form 
83 
 
FormVIII : Withdrawal 
form 
FormIX : Diet Sheet 
Form X : Adverse 
reaction  
Data Analysis: 
After enrolling the patients in the study a separate file for each 
patient was maintained and all forms was kept in the file. Whenever the 
patient visits OPD during the study period necessary entries were made in 
the assessment forms. 
The data entries and adverse events if any was monitored by the Head of 
the Department. 
 
Outcome of Treatment: 
 
The outcome treatment is mainly assessed by comparing the reduction 
in clinical symptoms and recurrence before and after treatment and assessed 
by comparing the safety parameters before and after treatment 
. 
     Adverse effect and Serious effect Management: 
 
If the trial patient develops any adverse reactions the patient would 
referred to the Pharmacovigilance department of Nanju Maruthuvam and 
documented. For any adverse effect the investigator was given the proper 
management in the OPD. 
 
Ethical issues: 
 
1. Informed consent was obtained from the patient after explaining about 
the clinical trial in an understandable language. 
 
2. After the consent of the patient (through consent) if they fit in the 
criteria they was  enrolled in the study. 
 
3. Treatment was provided free of cost. 
 
4. Concomitant medicines were  used if there is any need. 
 
5. The patients who are excluded (as per the exclusion criteria) were 
referring to OPD. 
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Analysis of Trial medicine: 
 
1. The acute and sub-Chronic toxicity study was carried out in 
National Institute of Siddha,Tambaram sanatorium Chennai-47 
2. The Physiochemical analysis was performed in Noble Research 
Solutions, Chennai. 
3. Observation made from patients with sign and symptoms of the 
disease and their prognosis were recorded. 
 
NORMAL VALUES - WHO CRITERIA: 
 
The WHO reference values for a normal semen analysis are defined as given 
Below. 
 
 
             Volume – 2 ml or more 
             Total sperm count - 20 million per ejaculate or   
       Spermconcentration - 20 million per   
        ejaculate or more pH – 7.2 or higher  Motility -  
    50 % or more motile 
             25% or more with progressive motility, within 60 minutes of       
 ejaculation Motility is graded from a to d according to WHO manual criteria, 
–           Fast progressive. Sperms are those which swim forward fast in a        
straight line, like guidedmissiles 
– Slowprogressive. 
Sperms swim forward, but either in a curved or crooked line or slowly. c             
–           Non progressive. 
Sperms move their tails, but do not move forward. (local motility only ) 
– Immotile. Sperms do not move atall.Sperms of grade c & d are considered poor. 
 
MORPHOLOGY: 
      Head - The head should be oval and smooth. 
      Mid piece - the mid piece should be straight and slightly thicker  
     than the tail. 
                 Tail - the tail should be single, unbroken, straight and without coi 
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Outcome of Treatment 
The outcome treatment is mainly assessed to improve the 
sperm count at least 20% and Sexual Health Score by comparing the 
reduction in clinical symptoms and recurrence  before and after treatment 
and assessed by comparing the safety parameters before and aftertreatment. 
 
Adverse effect and Serious effect Management: 
If the trial patient develops any adverse reactions the patient was  
referred to the Pharmacovigilance department of Nanju Maruthuvam 
National Institute of Siddha and documented. For any adverse effect the 
investigator will give the proper management in theOPD. 
Ethical issues 
1. Informed consent was  obtained from the patient after explaining 
 about the clinical trial in an understandablelanguage. 
2. After the consent of the patient (through consent) if they fit in the 
 criteria they was  enrolled in thestudy. 
3. Treatment was  provided free ofcost. 
4. Concomitant medicines was  used if there is anyneed. 
 
5. The patients who are excluded (as per the exclusion criteria) was  
  referring to OPD. 
 
Analysis of Trial medicine: 
1. The acute and sub-Chronic toxicity study was carried out in National 
 Institute of Siddha ,Chennai-47 
2. The physiochemical analysis was performed  in Noble Research 
 Solutions Chennai  
        3.       Observation made from patients with sign and symptoms of the 
 disease and their prognosis wererecorded. 
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RESULTS AND OBSERVATION 
The study on Aan maladu was carried out in 40 patients in the Department of 
Sirappu  Maruthuvam, National Institute of Siddha, Chennai-47 attached to 
Ayothidass Pandithar Hospital during 2016-2018  were analysed. The observation 
were made and tabulated with following criteria. 
 
 AgeDistribution 
 Kaalam 
 Thinai 
 Occupationalstatus 
 Socio economicstatus 
 Foodhabits 
 Personalhabits 
 Symptoms 
 Mukkutram- Vaatham, Pitham, Iyyam 
 Ezhu UdalKattugal 
 EnvagaiThervugal 
 Naadi 
 Neikuri 
 Clinical Progress 
 SemenAnalysis 
 Sexual Health Score 
 Grading ofResults
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BEFORE TREATMENT (GROUP I MEDICINE ONLY) 
TC- Total Count, DC- Differential Count, P- Polymorph, L- Lymphocytes, E- Eosinophil, HB- Haemoglobin, ESR- Erythrocytes 
Sedimentation Rate, Alb- Albumin, Sug- Sugar, Dep- Deposits, OPC- Occasional Pus Cells, OEC- Occasional Epithelial Cells, FPC- Few 
Pus Cells
 
S.No. 
 
OP.No. 
 
Age 
HEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
Tc 
Cu/mm 
D
c 
ES
R 
Hb 
(Gm.) 
Alb Sug Dep Ova Cys
t 
P L E 1/2hr 1 hr. 
1. I75584 39 9700 45 32 3 2 5 14 Nil Nil OPC Nil Nil 
2. J21944 26 9300 57 33 5 5 5 12.8 Nil Nil OPC Nil Nil 
3. J73812 33 9400 58 42 6 10 5 12.5 Nil Nil OPC Nil Nil 
4. J99050 37 10600 57 36 2 7 15 13 Nil Nil OPC Nil Nil 
5. J44749 40 9400 48 35 7 8 17 14,8 Nil Nil OPC Nil Nil 
6. H88868 27 10700 58 30 4 15 25 11.9 Nil Nil OPC Nil Nil 
7. J91432 32 9700 55 41 2 6 18 13.3 Nil Nil OPC Nil Nil 
8. J89161 31 9800 66 39 8 7 10 12 Nil Nil FPC Nil Nil 
9. J35031 42 10300 60 30 4 8 15 14 Nil Nil OPC Nil Nil 
10. J14466 34 10200 57 37 6 10 20 14.8 Nil Nil OEC Nil Nil 
11. F99587 36 9200 62 42 3 5 8 12.9 Nil Nil OPC Nil Nil 
12. J92651 34 9500 49 37 2 2 5 13 Nil Nil OPC Nil Nil 
13. J51711 34 9600 51 32 5 6 10 11 Nil Nil FPC Nil Nil 
14. K03734 42 8900 58 36 4 5 8 15 Nil Nil OEC Nil Nil 
15. J95223 34 9300 55 34 6 5 8 12.7 Nil Nil OPC Nil Nil 
16. H52513 27 10500 60 42 6 9 18 13.9 Nil Nil OPC Nil Nil 
17. J87368 30 8700 52 40 7 15 25 15 Nil Nil OPC Nil Nil 
18. J92653 30 9600 67 38 8 10 20 14.4 Nil Nil Nil Nil Nil 
19. J92647 33 9600 58 37 3 12 25 12.7 Nil Nil Nil Nil Nil 
20. J45803 33 9800 57 35 2 8 15 14.2 Nil Nil Nil Nil Nil 
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AFTER TREATMENT (GROUP – I   MEDICINE ONLY) 
 
 
 
 
S.No. 
 
OP.No. 
 
 
 
Age 
HEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
Tc 
Cu/mm 
D
c 
ES
R 
Hb 
(Gm.) 
Alb Sug Dep Ova Cys
t 
P L E 1/2hr 1 hr. 
1. I75584  30 9800 55 36 3 3 6 14.8 Nil Nil Nil Nil Nil 
2. J21944  30 9700 57 38 4 3 8 13.8 Nil Nil OPC Nil Nil 
3. J73812  27 9800 60 42 6 9 10 12.9 Nil Nil Nil Nil Nil 
4. J99050  30 10600 59 39 5 7 15 13.7 Nil Nil OPC Nil Nil 
5. J44749  51 9700 55 40 8 4 10 14.8 Nil Nil Nil Nil Nil 
6. H88868  30 10700 60 35 4 10 18 13.9 Nil Nil FPC Nil Nil 
7. J91432  35 10100 58 41 3 6 12 13.4 Nil Nil Nil Nil Nil 
8. J89161  34 9800 66 40 8 6 10 12.8 Nil Nil Nil Nil Nil 
9. J35031  44 10300 60 34 3 8 16 14 Nil Nil OPC Nil Nil 
10. J14466  30 10200 55 39 6 10 18 14.8 Nil Nil Nil Nil Nil 
11. F99587  33 9600 62 45 3 3 8 13 Nil Nil Nil Nil Nil 
12. J92651  27 10200 54 38 2 2 6 13.2 Nil Nil Nil Nil Nil 
13. J51711  21 9700 51 37 8 5 9 12 Nil Nil Nil Nil Nil 
14. K03734  35 9100 58 36 4 3 8 15 Nil Nil Nil Nil Nil 
15. J95223  30 9600 59 40 6 2 8 14 Nil Nil Nil Nil Nil 
16. H52513  37 10500 60 42 6 9 18 14 Nil Nil OPC Nil Nil 
17. J87368  34 9700 60 40 3 15 20 15 Nil Nil Nil Nil Nil 
18. J92653  32 9600 67 37 8 10 18 14.4 Nil Nil Nil Nil Nil 
19. J92647  27 9800 58 39 3 8 15 13.8 Nil Nil Nil Nil Nil 
20. J45803  30 9700 62 36 2 5 10 15 Nil Nil Nil Nil Nil 
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BEFORE TREATMENT (GROUP II  MEDICINE WITH YOGAM THERAPY 
 
- 
 
 
 
S.No. 
 
OP.No. 
 
Age 
HEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
Tc 
Cu/mm 
Dc ESR Hb 
(Gm.) 
Alb Sug Dep Ova Cyst 
P L E 1/2hr 1 hr. 
1. I95862 31 9900 55 36 3 3 6 14.8 Nil Nil Nil Nil Nil 
2. K01853 37 9600 57 38 4 3 8 13.8 Nil Nil OPC Nil Nil 
3. H71796 32 9700 60 42 6 9 10 12.9 Nil Nil Nil Nil Nil 
4. I77003 31 10100 59 39 5 7 15 13.7 Nil Nil OPC Nil Nil 
5. I81689 32 9800 55 40 8 4 10 14.8 Nil Nil Nil Nil Nil 
6. H14287 37 10500 60 35 4 10 18 13.9 Nil Nil FPC Nil Nil 
7. J32737 37 9900 58 41 3 6 12 13.4 Nil Nil Nil Nil Nil 
8. K04023 41 9600 66 40 8 6 10 12.8 Nil Nil Nil Nil Nil 
9. K06217 30 10400 60 34 3 8 16 14 Nil Nil OPC Nil Nil 
10. J92655 37 10200 55 39 6 10 18 14.8 Nil Nil Nil Nil Nil 
11. J33777 34 9700 62 45 3 3 8 13 Nil Nil Nil Nil Nil 
12. J89599 38 10200 54 38 2 2 6 13.2 Nil Nil Nil Nil Nil 
13. J41481 27 9700 51 37 8 5 9 12 Nil Nil Nil Nil Nil 
14. K14518 33 9200 58 36 4 3 8 15 Nil Nil Nil Nil Nil 
15. I69657 38 9900 59 40 6 2 8 14 Nil Nil Nil Nil Nil 
16. J41481 26 9700 60 42 6 9 18 14 Nil Nil OPC Nil Nil 
17. K01067 42 9900 60 40 3 15 20 15 Nil Nil Nil Nil Nil 
18. J95313 29 9800 67 37 8 10 18 14.4 Nil Nil Nil Nil Nil 
19. F03268 38 10200 58 39 3 8 15 13.8 Nil Nil Nil Nil Nil 
20. K18433 32 9600 62 36 2 5 10 15 Nil Nil Nil Nil Nil 
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AFTER TREATMENT (GROUP II  MEDICINE WITH YOGAM THERAPY 
 
S.No. 
 
OP.No. 
 
Age 
HEMATOLOGICAL REPORT URINE ANALYSIS STOOL EXAMINATION 
Tc 
Cu/mm 
Dc ESR Hb 
(Gm.) 
Alb Sug Dep Ova Cyst 
P L E 1/2hr 1 hr. 
1. I95862 31 9700 45 32 3 2 5 14 Nil Nil OPC Nil Nil 
2. K01853 37 9300 57 33 5 5 5 12.8 Nil Nil OPC Nil Nil 
3. H71796 32 9400 58 42 6 10 5 12.5 Nil Nil OPC Nil Nil 
4. I77003 31 10600 57 36 2 7 15 13 Nil Nil OPC Nil Nil 
5. I81689 32 9400 48 35 7 8 17 14,8 Nil Nil OPC Nil Nil 
6. H14287 37 10700 58 30 4 15 25 11.9 Nil Nil OPC Nil Nil 
7. J32737 37 9700 55 41 2 6 18 13.3 Nil Nil OPC Nil Nil 
8. K04023 41 9800 66 39 8 7 10 12 Nil Nil FPC Nil Nil 
9. K06217 30 10300 60 30 4 8 15 14 Nil Nil OPC Nil Nil 
10. J92655 37 10200 57 37 6 10 20 14.8 Nil Nil OEC Nil Nil 
11. J33777 34 9200 62 42 3 5 8 12.9 Nil Nil OPC Nil Nil 
12. J89599 38 9500 49 37 2 2 5 13 Nil Nil OPC Nil Nil 
13. J41481 27 9600 51 32 5 6 10 11 Nil Nil FPC Nil Nil 
14. K14518 33 8900 58 36 4 5 8 15 Nil Nil OEC Nil Nil 
15. I69657 38 9300 55 34 6 5 8 12.7 Nil Nil OPC Nil Nil 
16. J41481 26 10500 60 42 6 9 18 13.9 Nil Nil OPC Nil Nil 
17. K01067 42 8700 52 40 7 15 25 15 Nil Nil OPC Nil Nil 
18. J95313 29 9600 67 38 8 10 20 14.4 Nil Nil Nil Nil Nil 
19. F03268 38 9600 58 37 3 12 25 12.7 Nil Nil Nil Nil Nil 
20. K18433 32 9700 62 36 2 5 10 15 Nil Nil Nil Nil Nil 
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GROUP I (MEDICINE ONLY ) OPD PATIENTS BEFORE TREATMENT AND AFTER TREATMENT 
 
 
SL. 
NO. 
OP.NO. AGE SEMEN ANALYSIS 
BEFORE TREATMENT 
SEMEN ANALYSIS 
AFTERTREATMENT 
TOTAL NO. 
OF DAYS 
RESULT 
1. I75584 30 TSC – 13million/cu mm 
AM-20 % 
TSC – 50million/cu mm 
AM- 35% 
45 Days Good Improvement 
2. J21944 30 TSC –17 million/cu mm 
AM- 15%
**
 
TSC – 50million/cu mm 
AM- 30% 
45 Days GoodImprovement 
3. J73812 27 TSC – 4million/cu mm 
AM-20 % 
TSC –10 million/cu mm 
AM-30 % 
45 Days Poor Improvement 
4. J99050 30 TSC –20 million/cu mm 
AM-20 % 
TSC –70 million/cu mm 
AM- 48% 
45 Days GoodImprovement 
5. J44749 50 TSC –08 million/cu mm 
AM-8 %
**
 
TSC – 17million/cu mm 
AM-25 % 
45 Days Moderate Improvement 
6. H88868 30 TSC –20 million/cu mm 
AM- 10% 
TSC – 60million/cu mm 
AM- 40% 
45 Days GoodImprovement 
7. J91432 35 TSC –15 million/cu mm 
AM-5 % 
TSC – 60million/cu mm 
AM- 50% 
45 Days GoodImprovement 
8. J89161 34 TSC –17 million/cu mm 
AM- 07% 
TSC – 25million/cu mm 
AM- 15% 
45 Days Poor Improvement 
9. J35031 44 TSC – .08million/cu 
mm AM- 24% 
TSC –15 million/cu mm 
AM- 25% 
45 Days PoorImprovement 
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10. J14466 30 TSC –12.7 million/cu mm 
AM-22% 
TSC –70 million/cu mm 
AM-45 % 
45 Days GoodImprovement 
11. F99587 33 TSC –5 million/cu mm 
AM- 8% 
TSC –19 million/cu mm 
AM-22 % 
45 Days Moderate Improvement 
12. J92651 27 TSC – 4million/cu mm 
AM- 10% 
TSC – 14million/cu mm 
AM- 50% 
45 Days Poor Improvement 
13. J51711 21 TSC – 22million/cu mm 
AM- 10% 
TSC – 35million/cu mm 
AM- 40% 
45 Days Moderate Improvement 
14. K03734 35 TSC –12 million/cu mm 
AM-15 % 
TSC – 15million/cu mm 
AM- 20% 
45 Days Poor Improvement 
15. J95223 30 TSC –2 million/cu mm 
AM- 7% 
TSC –60 million/cu mm 
AM-35 % 
45 Days Good Improvement 
16. H52513 37 TSC –14 million/cu mm 
AM-10 % 
TSC –35 million/cu mm 
AM-44 % 
45 Days Moderate Improvement 
17. J87368 34 TSC – 30million/cu mm 
AM- 15 % 
TSC –45 million/cu mm 
AM-30 % 
45 Days Good Improvement 
18. J92653 32 TSC –7.15 million/cu mm 
AM- 10 % 
TSC –55 million/cu mm 
AM- 25% 
45 Days Moderate Improvement 
19. J92647 27 TSC –15 million/cu mm 
AM- 8 % 
TSC –42 million/cu mm 
AM-22 % 
45 Days Moderate Improvement 
20. J45803 30 TSC –11.7 million/cu mm 
AM- 8.5 % 
TSC –40 million/cu mm 
AM- 35% 
45 Days Good Improvement 
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GROUP II (MEDICINE WITH YOGAM THERAPY ) OPD PATIENTS BEFORE TREATMENT AND AFTER TREATMENT 
 
 
 
 
SL. 
NO. 
OP.NO. AGE SEMEN ANALYSIS 
BEFORE TREATMENT 
SEMEN ANALYSIS 
AFTERTREATMENT 
TOTAL NO. 
OF DAYS 
RESULT 
1. I95862 31 TSC – 13million/cu mm 
AM-20 % 
TSC – 50million/cu mm 
AM- 55% 
45 Days Good Improvement 
2. K01853 37 TSC –12 million/cu mm 
AM- 15%
**
 
TSC – 70million/cu mm 
AM- 60% 
45 Days GoodImprovement 
3. H71796 32 TSC – 4million/cu mm 
AM-20 % 
TSC –10 million/cu mm 
AM-50 % 
45 Days Poor Improvement 
4. I77003 31 TSC –10 million/cu mm 
AM-20 % 
TSC –70 million/cu mm 
AM- 58% 
45 Days GoodImprovement 
5. I81689 32 TSC –18 million/cu mm 
AM-8 %
**
 
TSC – 70million/cu mm 
AM-55 % 
45 Days Good Improvement 
6. H14287 37 TSC –20 million/cu mm 
AM- 10% 
TSC – 60million/cu mm 
AM- 60% 
45 Days GoodImprovement 
7. J32737 37 TSC –15 million/cu mm 
AM-5 % 
TSC – 60million/cu mm 
AM- 50% 
45 Days GoodImprovement 
8. K04023 41 TSC –17 million/cu mm 
AM- 07% 
TSC – 24million/cu mm 
AM- 25% 
45 Days Poor Improvement 
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9. K06217 30 TSC – 19million/cu mm 
AM- 24% 
TSC –59 million/cu mm 
AM- 53% 
45 Days GoodImprovement 
10. J92655 37 TSC –12.7 million/cu mm 
AM-22% 
TSC –70 million/cu mm 
AM-65 % 
45 Days GoodImprovement 
11. J33777 34 TSC –5 million/cu mm 
AM- 8% 
TSC –27 million/cu mm 
AM-22 % 
45 Days Moderate Improvement 
12. J89599 38 TSC – 4million/cu mm 
AM- 10% 
TSC – 14million/cu mm 
AM- 50% 
45 Days Poor Improvement 
13. J41481 27 TSC – 22million/cu mm 
AM- 10% 
TSC – 35million/cu mm 
AM- 47% 
45 Days Moderate Improvement 
14. K14518 33 TSC –25 million/cu mm 
AM-35 % 
TSC – 75million/cu mm 
AM- 50% 
45 Days Good Improvement 
15. I69657 38 TSC –2 million/cu mm 
AM- 7% 
TSC –60 million/cu mm 
AM-35 % 
45 Days Good Improvement 
16. J41481 26 TSC –14 million/cu mm 
AM-32 % 
TSC –105 million/cu mm 
AM-54 % 
45 Days Good Improvement 
17. K01067 42 TSC – 30million/cu mm 
AM- 15 % 
TSC –45 million/cu mm 
AM-30 % 
45 Days Good Improvement 
18. J95313 29 TSC –7.15 million/cu mm 
AM- 10 % 
TSC –60 million/cu mm 
AM- 58% 
45 Days Good Improvement 
19. F03268 38 TSC –15 million/cu mm 
AM- 8 % 
TSC –42 million/cu mm 
AM-29 % 
45 Days Moderate Improvement 
20. K18433 32 TSC –11.7 million/cu mm 
AM- 8.5 % 
TSC –90 million/cu mm 
AM- 57% 
45 Days Good Improvement 
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SEXUAL HEALTH SCORE 
The scoring system developed by Mehra and Singh (1995) 
 
                      GROUP-I (MEDICINE ONLY)                                                                                GROUP-II (MEDICINE WITH YOGAM THERAPY) 
 
  
S.No. 
 
OP.No. 
 
Age 
 
SHC 
13/13 
BT AT 
1. I75584 30 7 9 
2. J21944 30 9 10 
3. J73812 27 6 9 
4. J99050 30 5 8 
5. J44749 50 4 6 
6. H88868 30 5 8 
7. J91432 35 8 7 
8. J89161 34 4 6 
9. J35031 44 2 6 
10. J14466 30 8 9 
11. F99587 33 6 11 
12. J92651 27 10 11 
13. J51711 27 9 9 
14. K03734 35 5 7 
15. J95223 30 8 10 
16. H52513 37 7 9 
17. J87368 34 5 7 
18. J92653 32 4 6 
19. J92647 27 7 9 
20. J45803 30 7 11 
 
S.No. 
 
OP.No. 
 
Age 
 
SHC 
13/13 
BT AT 
1. I95862 31 5 10 
2. K01853 37 7 12 
3. H71796 32 5 10 
4. I77003 31 8 12 
5. I81689 32 9 12 
6. H14287 37 4 7 
7. J32737 37 5 10 
8. K04023 41 7 12 
9. K06217 30 6 12 
10. J92655 37 8 11 
11. J33777 34 6 12 
12. J89599 38 5 10 
13. J41481 27 5 9 
14. K14518 33 3 9 
15. I69657 38 6 10 
16. J41481 26 6 12 
17. K01067 42 6 9 
18. J95313 29 8 12 
19. F03268 38 6 11 
20. K18433 32 8 12 
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GROUP I (MEDICINE ONLY ) OPD PATIENTS 
SEMEN ANALYSIS 
 
 
 
Sl. No Result No of cases 20 Percentage 
1 Good 9 45% 
2 Moderate 6 30% 
3 Poor 5 25% 
 
Observation: 
Among 20 cases 9cases were good improvement, 6 cases were moderate improvement,  
5 cases Poor improvement. 
 
 
 
 
GROUP II  (MEDICINE ALONG WITH YOGAM THERAPY ) OPD PATIENTS 
SEMEN ANALYSIS 
 
 
Sl. No Result No of cases 20 Percentage 
1 Good 14 70% 
2 Moderate 3 15% 
3 Poor 3 15% 
 
 
 
Observation: 
Among 20 cases 14 cases were good improvement, 3 cases were moderate improvement,  
3 cases Poor improvement. 
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Age Distribution: 
 
Sl. No Age No. of Patients/40 Percentage 
1. 21-30 15 37.5% 
2. 31-40 21 52.5% 
3. 41-50 2 10% 
 
 
 
 
 
 
 
 
 
Inference: 
 
According to the above mentioned data 37.5% of patients were in age group 
21- 30 years, 52.5% of patients were in age group 31-40 years and 10% of patients 
were in age group 41-50 years. 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
21-30 AGE 31-40 AGE 41-50 AGE
AGE DISTRIBUTION
PERCHANTAGE
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Thinai: 
 
Sl. No Thinai No. of Patients/40 Percentage 
1 Kurinji 0 0% 
2 Mullai 0 0% 
3 Marutham 14 35% 
4 Neithal 26 65% 
5 Paalai 0 0% 
 
 
 
 
Inference: 
 
According to the above mentioned data 65% of patients were from Neithal, 
and 35% of patients were from Marutham. 
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Paruva kaalam: 
 
Sl. 
No 
Paruva kaalam Months No. of 
Patients/ 
40 
Percentage 
1. Kaar kaalam Avani, puratasi (Mid Aug- Mid Oct) 8 20% 
2. Koothir kaalam Iyppasi, Kaarthigai (Mid Oct- Mid Dec) 16 40% 
3. Munpani kaalam Margazhi, Thai (Mid Dec- Mid Feb) 8 20% 
4. Pinpani kaalam Maasi, Panguni (Mid Feb- Mid April) 0 0% 
5. Elavenil kaalam Chithirai, Vaigasi (Mid April- Mid June) 6 15% 
6. Mudhuvenil
kaalam 
Aani, Aadi (Mid June- Mid Aug) 2 5% 
 
 
 
 
Inference: 
 
40% of cases came in Koothir kaalam, 20% of cases in Kaar kaalam & 
Munpani kaalam, 15% of cases came in Elavenil kaalam and 5% cases in Mudhuvenil 
kaalam 
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Occupational Status: 
 
Sl. No Occupational Status No. ofPatients/40 Percentage 
1. Drivers 16 40% 
2. Labourers 10 25% 
3. Professionals 8 20% 
4. Businessman 6 15% 
 
 
 
 
Inference: 
 
40% of cases were Drivers, 25% of cases were Labourers, 20% of cases were 
Professionals and 15% of cases were Businessman. 
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Socio Economic Status: 
 
Sl. No Socio Economic Status No. of Patients/40 Percentage 
1. Low income group 
(below 25000/ Month) 
 
18 
 
45% 
2. Middle income group 
 
( 25000-50000/ Month) 
 
12 
 
30% 
3. High income group 
(above 50000/ Month) 
 
10 
 
25% 
 
 
Inference: 
 
45% of patients belong to low income group, 30% of patients belongs to 
middle income group and 25% of patients belongs to high income group. 
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Food Habits: 
 
Sl. No Food Habits No. ofPatients/40 Percentage 
1. Vegetarian Diet 08 20% 
2. 
Mixed Diet 32 80% 
 
 
Inference: 
 
80% of patients were mixed diet (including non-vegetarian) 
20% of patients were vegetarian. 
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Personal Habits: 
 
Sl. No Personal Habits No. ofPatients/40 Percentage 
1. Smoker 08 20% 
2. Alcoholic 06 15% 
3. Both smoker and 
alcoholic 
14 35% 
4. Tobacco chewing 0 0% 
5. Non intake of the 
above 
12 30% 
 
 
 
 
Inference: 
 
35% of cases were both smokers and alcoholic, 
20% of cases werealcoholic 
15% of cases werealcoholic 
 
And 30% of cases were None of the above habits 
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Vaatham: 
 
Sl. No Vaatham No. of Patients/40 Percentage 
1. Pranan 0 0% 
2. Abanan 20 100% 
3. Vyanan 6 30% 
4. Udhanan 0 0% 
5. Samanan 0 0% 
6. Nagan 0 0% 
7. Koorman 8 40% 
8. Kirukaran 0 0% 
9. Devathathan 14 70% 
10. Dhananjeyan 0 0% 
 
 
Inference: 
 
Abanan was affected in 100% of patients, koorman was affected in 40% of 
patients and vyanan was affected in 30% of patients, Devathathan was affected in 
70% of patients. 
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Pitham: 
 
Sl. No Pitham No. of Patients/40 Percentage 
1. Anar Pitham 0 0% 
2. Ranjaga Pitham 10 100% 
3. Sadhaga Pitham 10 100% 
4. Aalosaga Pitham 04 40% 
5. Prasaga Pitham 03 35% 
 
 
 
 
Inference: 
 
Ranjaga Pitham and Sadhaga Pitham was affected in100% of patients, 
Aalosaga Pitham was affected in 40% of patients and Prasaga Pitham was affected in 
35% of patients. 
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Iyyam: 
 
Sl. No Iyyam No. of Patients/40 Percentage 
1. Avalambagam 0 0% 
2. Kilethagam 0 0% 
3. Pothagam 0 0% 
4. Tharpagam 8 40% 
5. Sandhigam 5 25% 
 
 
 
 
Inference: 
 
Tharpagam was affected in 40% of patients and Sandhigam was affected in 25% of 
patients. 
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Udal Kattugal: 
 
Sl. No Udal Kattugal No. of Patients/40 Percentage 
1. Saaram 20 100% 
2. Senner 0 0% 
3. Oon 0 0% 
4. Kozhuppu 0 0% 
5. Enbu 5 25% 
6. Moolai 0 0% 
7. Sukkilam 20 100% 
 
 
Inference: 
 
Saaram and Sukkilam were affected in 100% of patients and Enbu was affected in 
25% of patients. 
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Enn Vagai Thervu: 
 
Sl. No Enn Vagai Thervu No. of Patients/40 Percentage 
1. Naa 0 0% 
2. Niram 0 0% 
3. Mozhi 0 0% 
4. Vizhi 8 40% 
5. Naadi 20 100% 
6. Sparisam 0 0% 
7. Malam 0 0% 
8. Moothiram 0 0% 
 
 
Inference: 
 
Naadi was affected in 100% of patients and Vizhi was affected in 40% of patients. 
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Naadi: 
 
Sl. No Naadi No. of Patients/40 Percentage 
1. Vaathapitham 24 60% 
2. Pithavaatham 16 40% 
 
 
 
 
Inference: 
 
60% of patient‟ s Vaathapitham Naadi was felt and 40% of patient‟ s 
Pithavaatham Naadi was felt. 
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Neikkuri: 
 
Sl. No Neikkuri No. of Patients/40 Percentage 
1. Vali 
(spreads like snake) 
20 50% 
2. Azhal 
(spreads like ring) 
20 50% 
3. Iyyam 
(spreads like pearl) 
0 0% 
 
 
 
 
Inference: 
 
50% of cases show Vali Neikkuri and 50% of cases show Azhal Neikkuri 
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Clinical Progress: 
 
Sl. 
No 
Symptoms No. ofPatients/40 Percentage 
BT AT BT AT 
1. Premature Ejaculation 13 3 65% 15% 
2. Erectile Dysfunction 8 2 40% 10% 
3. Nocturnal Emission 10 2 50% 10% 
4. No Symptoms 4 4 20% 20% 
 
 
 
 
 
Inference: 
 
Before treatment 65% of cases had Premature Ejaculation, 40% of cases had Erectile 
Dysfunction and 50% of cases had Nocturnal Emission. 
After treatment Premature Ejaculation having 15% of cases, Erectile Dysfunction and 
Nocturnal Emission of cases respectively having 10% 
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Semen Analysis before treatment and after treatment: 
GROUP –I ( MEDICINE ONLY) 
 
Sl. No SPERM COUNT 
Million/cu mm 
No. of 
Patients/20 
Percentage 
BT AT BT AT 
1 1-10 million/cu mm 7 1 17.5% 2.5% 
2 11-20 million/cu mm 11 5 27.5% 12.5% 
3 21-30 million/cu mm 2 1 5% 2.5% 
4 31-40 million/cu mm Nil 3 Nil 7.5% 
5 41-50 million/cu mm Nil 4 Nil 10% 
6 51-60 million/cu mm Nil 4 Nil 10% 
7 61-70 million/cu mm Nil 2 10% 5% 
8 71-80 million/cu mm Nil Nil Nil Nil 
 
 
 
GROUP-II  (MEDICINE WITH YOGAMTHERAPY) 
 
Sl. No SPERM COUNT 
Million/cu mm 
No. of 
Patients/20 
Percentage 
BT AT BT AT 
1 1-10 million/cu mm 6 1 15% 2.5% 
2 11-20 million/cu mm 11 1 27.5% 2.5% 
3 21-30 million/cu mm 3 2 7.5% 5% 
4 31-40 million/cu mm Nil 1 Nil 2.5% 
5 41-50 million/cu mm Nil 3 Nil 7.5% 
6 51-60 million/cu mm Nil 5 Nil 12.5% 
7 61-70 million/cu mm Nil 4 Nil 10% 
8 71-80 million/cu mm Nil 1 Nil 2.5% 
9 81-90 million/cu mm Nil 1 Nil 2.5% 
10 91-100 million/cu mm Nil Nil Nil Nil 
11 101-110 million/cu mm Nil  1 Nil 2.5% 
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Inference: 
GROUP I MEDICINE ONLY 
 
Before treatment 
17.5% of cases sperm count had 1-10 million/cumm, 27.5% of cases sperm 
count had 11-20 million/cumm, 5% cases sperm count had 21-30 million/cumm, 10% 
of cases sperm count had 61-70 million/cumm (This 10% of cases Active Motility 
were below normal level) 
 
 
After treatment 
 
2.5% of cases sperm count had 1-10 million/cumm, 12.5% of cases sperm 
count had 11-20 million/cumm, 2.5% cases sperm count had 21-30 million/cumm, 
7.5% of cases sperm count had 31-40 million/cumm, 10% of cases sperm count had 
41-50 million/cumm, 10% of cases sperm count had 51-60 million/cumm, 5% of 
cases sperm count had 61-70 million/cumm,  
 
 
GROUP II  MEDICINE WITH YOGAM THERAPY  
Before treatment 
15% of cases sperm count had 1-10 million/cumm, 27.5% of cases sperm count 
had 11-20 million/cumm,7. 5% cases sperm count had 21-30 million/cumm,  
 
After treatment 
 
2.5% of cases sperm count had 1-10 million/cumm, 2.5% of cases sperm count 
had 11-20 million/cumm, 5% cases sperm count had 21-30 million/cumm, 2.5% of 
cases sperm count had 31-40 million/cumm, 7.5% of cases sperm count had 41-50 
million/cumm, 12.5% of cases sperm count had 51-60 million/cumm, 10% of cases 
Sperm count had 61-70 million/cumm, 2.5% of cases sperm count had 71-80 
million/cumm, 2.5% of cases sperm count had 81-90million/cumm, 2.5% of cases 
sperm count had 101-110 million/cumm. 
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SEXUAL HEALTH SCORE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO  
 
OPD 
NO 
 
                  SHC 
13/13 
 
 
             SHC  % 
(PERCENTAGE) 
Results 
Score 13/13 
BT AT BT AT BT AT 
1. I75584 7 9 53 69 Excellent Excellent 
2. J21944 9 10 69 76 Excellent Excellent 
3. J73812 6 9 46 69 Excellent Excellent 
4. J99050 5 8 38 61 Excellent Excellent 
5. J44749 4 6 30 46 VeryGood Excellent 
6. H88868 5 8 38 61 Excellent Excellent 
7. J91432 8 7 61 53 Excellent Excellent 
8. J89161 4 6 30 46 VeryGood Excellent 
9. J35031 2 6 15 46 Moderate Excellent 
10. J14466 8 9 61 69 Excellent Excellent 
11. F99587 6 11 46 84 Excellent Excellent 
12. J92651 10 11 76 84 Excellent Excellent 
13. J51711 9 9 69 69 Excellent Excellent 
14. K03734 5 7 38 69 Excellent Excellent 
15. J95223 8 10 61 76 Excellent Excellent 
16. H52513 7 9 53 69 Excellent Excellent 
17. J87368 5 7 38 53 Excellent Excellent 
18. J92653 4 6 30 46 VeryGood Excellent 
19. J92647 7 9 53 69 Excellent Excellent 
20. J45803 7 11 53 84 Excellent Excellent 
S.NO  
 
OPD NO 
 
                  SHC 
13/13 
 
 
             SHC  
% 
 
Results 
BT AT BT AT BT AT 
1. I95862 5 10 38 76 Excellent Excellent 
2. K01853 7 12 53 92 Excellent Excellent 
3. H71796 5 10 38 76 Excellent Excellent 
4. I77003 8 12 61 92 Excellent Excellent 
5. I81689 9 12 69 92 Excellent Excellent 
6. H14287 4 7 38 76 Excellent Excellent 
7. J32737 5 10 38 76 Excellent Excellent 
8. K04023 7 12 53 92 Excellent Excellent 
9. K06217 6 12 46 92 Excellent Excellent 
10. J92655 8 11 61 84 Excellent Excellent 
11. J33777 6 12 46 92 Excellent Excellent 
12. J89599 5 10 38 76 Excellent Excellent 
13. J41481 5 9 38 69 Excellent Excellent 
14. K14518 3 9 23 69 Good Excellent 
15. I69657 6 10 46 76 Excellent Excellent 
16. J41481 6 12 46 92 Excellent Excellent 
GROUP II 
MEDICINE 
WITH 
YOGAMTHER
APY 
                                                        
GROUP I 
MEDICINE 
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SEMEN ANALYSIS 
S.No Results No.of .Patients 40 Perchantage 
1 Good 23 57.5% 
2 Moderate 9 22.5% 
3 Poor 8 20% 
 
17. K01067 6 9 46 69 Excellent Excellent 
18. J95313 8 12 30 46 Excellent Excellent 
19. F03268 6 11 46 84 Excellent Excellent 
20. K18433 8 12 61 92 Excellent Excellent 
SEXUAL HEALTH SCORE 
S.No Results No.of.Patients 40 Perchantage 
1 Excellent 40 100% 
2 Very Good 0 0 
3 Good 0 0 
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DISCUSSION 
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DISCUSSION: 
One of the Predominant disorders that endanger human species is 
INFERTILITY in Both men and women. The incidence of infertility is 
comparatively higher in males became of the drastic changes in human life 
style – irregular food habits, high calorie food items, fast foodbehavioral 
changes. Environmental toxins and changed compounds used for dispensing 
variousailments. 
It has been suggested that the average sperm count has been decreasing 
over the past 50 years. 
Aan maladu as stated in yugi vaidya chindhamani has close resemblance 
with male infertility in Allopathic Medicine. 
In my study 40 patients were treated in outpatient department of Sirappu 
Maruthuvam department, Ayothidass Pandithar Hospital attached with National 
Institute of Siddha, Chennai – 47. 
All patients were subjected to preliminary investigations which include 
hematological, urine examination, Semen Analysis,Sexual Health Score  before 
and after Treatment. 
Before Treatment purgative was given to all patients to balance the 
altered three dhosas (vaatha, pitha, kabha). 
The Trial Medicine THETRAN ILAGAM was administered from the 
next day onward, course of the Treatment is 45 days. 
Age Distribution: 
According to this study age distribution was 37.5% of patients were in age 
group 21-30 years, 52.5% of patients were in age group 31-40 years and 10% of 
patients were in age group 41-50years. 
Distribution of Thinai: 
According to this study 65% of the Patients came from Neithal because 
Chennai and surrounding areas come under Neithal thinai, and 35% of patients 
were from Marutham. 
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Paruvakalam: 
 
According to this study 40% of cases came in Koothir kaalam, 20% of cases 
in Kaar kaalam & Munpani kaalam, 15% of cases came in Elavenil kaalam and 5% 
cases in Mudhuvenil kaalam. Seasonal incidence is not affected their disease, 
maleinfertility. 
Occupational Status: 
40%of the patients were Drivers, 25% of patients were working as 
Labourers, 15% of patients are Businessman, and 20% of patients are 
Professionals. 
Socio Economic Status: 
The majority of the Patients affected are from poor socio economic 
status. Poor hygienic conditions expose to polluted atmosphere and lower 
immune response made them prone to the disease. 
Food Habits: 
20% Patients were pure vegetarian, 80% were Mixed Diet (including 
non-vegetarian). Though a non-vegetarian diet account is not a reason for the 
occurrence of male infertility. 
Personal Habits: 
In my study 15% of the Patients were using alcohol, 20%were smoker, 
35% were having both smoker and alcohol and 30% of the patients were non 
intake of above this. The observation coincides with the conception that male 
infertility the disease may be due to smoking, Alcohol consumption. 
Symptoms: 
According to this study 65% of cases came with complaints of Premature 
Ejaculation, 40% of cases came with complaints of Erectile Dysfunction, and 50% of 
cases came with complaints of Nocturnal Emission 20% of cases had No Symptoms. 
Classification of Results According To Vali, Azhal and Iyyam:- 
Vali: 
 Spermatogenesis, Premature Ejaculation, Nocturnal Emission is due to 
deranged AbanaVayu. 
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 Erectile dysfunction is due to derangedviyanan. 
 In 100% patients abanan was affected, viyanan was affected 40% of 
patients. 
 Koorman affected in 40% ofcases. 
 And Devathathan affected in 70% ofcases 
Azhal: 
Ranjaga pitham and Sadhaga pitham were affected in 100% of cases. 
Aalosaga Pitham was affected in 40% of Patients. Prasaga Pitham was affected in 
35% of patients. 
Iyyam: 
 
Tharpagam may be affected in Patients hot atmosphere. 40% of patients 
Tharpagam were affected. 25 % of Patients santhigam was affected & produce 
Joint Pain. 
Udal Kattugal: 
Both bodily and mental weakness arises when saaram was affected. In 
100% of patients both the saaram and sukkilam were affected. In 25% of cases 
enbu was affected. 
Envagai Thervu 
Naadi was affected in 100% of patients and 40% of patients vizhi was 
affected. 
Naadi 
In 40% of patients Vaathapitha Naadi was felt and 60% of patients 
Pithavaatha Naadi were felt. 
Neikuri 
50% of cases show azhal neikuri (spreads like ring) and 50% of cases 
show vali neikuri (spreads like snake). 
Clinical Progress: 
Before treatment 65% of cases had Premature Ejaculation, 40% of cases had 
Erectile Dysfunction and 50% of cases had Nocturnal Emission. 
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After treatment Premature Ejaculation having 15% of cases, Erectile 
Dysfunction and Nocturnal Emission of cases respectively having 
Semen Analysis: 
 
Before treatment 
 
25% of cases sperm count had 1-10 million/cumm, 50% of cases sperm count 
had 11-20 million/cumm, 15% cases sperm count had 21-30 million/cumm, 10% of 
cases sperm count had 61-70 million/cumm (This 10% of cases Active Motility were 
below normal level). 
After treatment 
 
5% of cases sperm count had 1-10 million/cumm, 10% of cases sperm count 
had 11-20 million/cumm, 5% cases sperm count had 21-30 million/cumm, 10% of 
cases sperm count had 31-40 million/cumm, 20% of cases sperm count had 41-50 
million/cumm, 25% of cases sperm count had 51-60 million/cumm, 20% of cases 
sperm count had 61-70 million/cumm, 5% of cases sperm count had 71-80 
million/cumm 
Group I  Patients 
Among 20 cases 9cases were good improvement, 6 cases were moderate improvement,  
5 cases Poor improvement. 
Group II Patients 
 Among 20 cases 14 cases were good improvement, 3 cases were moderate improvement,  
3 cases Poor improvement. 
All the 40 patients among the 23 cases were good inmprovement, 9 cases were moderate 
improvement, 8 patients were poor improvement. 
 
 
 
Trial Medicine: 
All the 40 (20) patients treated with the Trial Medicine THETRAN 
ILAGAM with milk, 20 patients trial medicine along with Yogam therapy 
twice a day for 48 days. The disease and treatment are based primarily on the 
derangement of Mukkutram, which again is based on  the Pancha bootham 
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theory. Incidence of Aan maladu and treatment are also based on these primary 
principles of Siddha medicine. The bootham raises azhal kuttram in the body 
and so as lead to general weakness and reduced sperm cell production. 
Increased azhal kuttram is brought to normal mainly by enippu suvai and 
thuvarpu suvai. These sweet and astringent tastes have the cool potency 
bynature. 
A. Earth + Water =Sweet 
B. Earth + Air =Astringent. 
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Thus they decrease the azhal kuttram. Sweet taste increases the 
spermatogenesis.  
 
Toxicological Evaluation: 
The drug also subjected to toxicological tests in rat models. The results 
revealed that the drug had very effective results. There were no signs of 
toxicity as could be judged by the absence of undesirable clinical 
manifestations. 
Bio Statistical study: 
The bio-statistical report of the clinical trial shows significant result. 
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SUMMARY 
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SUMMARY 
 
The aim of the study is to increase the sperm count and sperm motility in 
male infertility patient. The trial medicine Thetran Ilagam was prepared as per 
literature. The duration of the trial period is 45 days. The trial doseisThetran 
Ilagam 5gm.twiceadaywithcow‟ smilk.40 patients for the trial based on Inclusion 
and Exclusion criteria. Before treatment routine blood, urine and semen analysis 
taken in all 40 patients. This study has been approved by IEC of NIS [Date of IEC 
Approval & its number: NIS/IEC/2016/11-13/14.10.2016.. All 40 cases (20Group 
I & 20Group II) were treated in OPD of Ayothidoss Pandithar Hospital of 
National Institute of Siddha, Chennai-47. Patients were instructed to come for 
next review once in 7 days. 35 patients were come with clinical symptoms 
like premature ejaculation, erectile dysfunction, and nocturnal emission. 
The entire details of the patients were noted in the case sheet proforma.The 
detailed trial of Aan Maladu with reference to its aetiology, pathogenesis, 
investigations, clinical features, diagnosis and treatment with trial drugs was done. 
The results were observed by Semen Analysis and Sexual Health Score. All the 40 
patients among the 23(57.5%) cases were good inmprovement, 9(22.5 %) cases 
were moderate   improvement, and 8 (20%) patients were poor improvement. 
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CONCLUSION 
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CONCLUSION 
 
 The polyherbal formulation Thetran Ilagam exhibited no toxicity on short 
form administration. The quantitative outcome of Semen Analysis and 
Sexual Health score shows there is significant improved between at the 
start and end of treatment i.e the mean and standard deviation is from 
13.2±7.14 and 46.8 ± 23.2. The qualitative outcome shows encouraging 
results of All the 40 patients among the 23(57.5%) cases were good 
inmprovement, 9(22.5 %) cases were moderate   improvement, and 8 
(20%) patients were poor improvement.From the above results, the trail 
drugs “Thetran Ilagam” (Internal Medicine) is responded well for the 
treatment of Aan MaladuTherefore the author concluded that the yogam 
based intervention in the management of Aan maladu produced better 
outcome.. 
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BIOCHEMICAL ANALYSIS 
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ANNEXURE -II 
BIO-CHEMICAL ANALYSIS 
BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINES 
Preparation of Sodium Carbonate extract: 
2 gm of the sample drug is mixed 5 gm of Sodium carbonate and taken 
in a 100 ml beaker and 20 ml of distilled water is added. The solution is boiled 
for 10 minutes, cooled and then filtered. The filtrate is called sodium carbonate 
extract. 
S.No EXPERIMENT OBSERVATION INFERENCE 
I TEST FOR ACID RADICALS 
1a Test for Sulphate 
2 ml of the above prepared 
extract is taken in a test tube. To 
this add 2ml of 4% Ammonium 
oxalate solution. 
Absence of 
WhitePrecipitate 
Absent 
b 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off. 
Then 2ml barium chloride 
solution is added. 
Absence of 
WhitePrecipitate 
Absent 
2 Test for Chloride: 
2ml of extract is added with 
dilute nitric acid till the 
effervescence ceases. Then 2ml 
of silver nitrate solution is 
added. 
Absence of white 
precipitate 
Obtained 
Absent 
3 Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate solution and 2ml of 
concentrated nitric acid. 
Yellow precipitate 
Obtained 
Present 
140 
 
4 Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
Absence of white 
Precipitate 
Absent 
5 Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
Rotten egg smelling Present 
6 Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
Absent 
7a Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 
2ml of calcium chloride 
solution and heated. 
White precipitate Present 
b 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added. 
KMNO4 solution 
Discolourisation 
obtained 
Present 
8 Test for Nitrite 
3 drops of the extract is placed 
on a filter paper. On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
Absence of 
yellowish red colour 
Absent 
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9 Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
Absence of Green 
tinged flame 
Absent 
II TEST FOR BASIC RADICALS 
10 Test for lead 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution. 
Absence of Yellow 
Precipitate 
Absent 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloricacid 
in a watch glass and introduced 
into the non luminous partof 
the flame. 
Absence of Bluish 
green coloured 
flame. 
Absent 
b 2ml of the extract is added with 
excess of Ammonia solution 
Absence of deep 
Blue 
Absent 
12 Test for Aluminium 
To the 2 ml of extract. Sodium 
Hydroxide solution is added in 
drops to excess 
Absence of White 
Precipitate. 
Absent 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
Solution is added. 
Blood red colour Present 
b To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated Nitric Acid is 
added. 
Blood red colour 
obtained 
Present 
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14 Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of White 
precipitate. 
Absent 
15 Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
Absence of White 
precipitate. 
Absent 
16 Test for Magnesium 
2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of White 
precipitate. 
Absent 
17 Test for Ammonium 
2 ml of extract few ml of 
Nessler‟ s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
Absence of 
Reddish brown 
Precipitate 
Absent 
18 Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
Absence of Yellow 
precipitate 
Absent 
19 Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame 
Absence of Yellow 
colour flame 
Absent 
20 Test for Mercury 
2 ml of the extract is treated 
with 2 ml of Sodium 
Hydroxide solution. 
Absence of yellow 
Precipitate 
Absent 
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21 Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
Absence of 
Yellow precipitate 
Absent 
22 Test for Starch 
2ml of extract is treated with 
weak iodine solution 
Absence of 
Blue colour 
Absent 
23 Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added 10 drops of 
the extract and again boiled for 
2 minutes. The colour changes 
are noted. 
Green colour Present 
24 Test of the alkaloids 
2ml of the extract is treated 
with 2ml of potassium lodide 
solution. 
Absence of 
Red colour 
Absent 
25 Test of the proteins 
2ml of the extract is treated 
with 2ml of 5% NaOH ,mix 
well and add 2 drops of copper 
sulphate solution. 
Absence of 
Violet colour 
Absent 
 
 
RESULTS: 
 
The given sample (THETRAN ILAGAM) contains 
 
 Phosphate,
 Sulphide,
 Fluoride and Oxalate,
 Iron,
 Reducingsugar.
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ANNEXURE III 
PHYSICOCHEMICALANALYSIS 
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ANNEXURE –III 
 
 
 
 
 
 
  Sample Description
Project ID NRS/AS/0102/03/2018 
Source Dr.Karthik Nagarajan 
National Institute of Siddha , 
Tambaram  Sanatoruim,  
Chennai 600047,Tamilnadu, India 
 
Purpose Physicochemical Analysis 
Sample –ID TI 
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State Semi solid 
Appearance Dark Brown 
Nature Greasy touch 
Odor Strong Characteristic odour  
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 31.57  ±  3.15 
2.  Total Ash (%)  14.56  ±  0.66 
3.  Acid insoluble Ash (%) 16.07  ±  1.60 
4.  Water Soluble Ash (%) 12.93  ±  0.80 
5.  Alcohol Soluble Extractive (%) 11.61  ±  0.75 
6.  Water soluble Extractive (%) 9.03  ±  1.12 
       7. pH 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Project ID NRS/AS/0102/03/2018 
Name and Address of the Researcher Dr.Karthik Nagarajan 
National Institute of Siddha, Chennai 
Tamilnadu, India 
Parameter Requested by the Customer for 
Analysis 
Phytochemical Analysis 
Sample Received Post  
Sample –ID Thetran Ilagam 
TI 
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Extraction 
 
Sample Extraction were carried out with n-hexane , chloroform and the resulting extract was 
utilized for the phytochemical analysis 
PHYTOCHEMICAL ANALYSIS 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is           indicated by the formation of yellow color. 
Test for saponins:  
       To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
       To the test sample, ferric chloride was added, formation of a dark blue or greenish black 
color showed the presence of tannins. 
 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water bath, 
filtered and the hydrolysate is subjected to the following tests. To 2 ml of filtered 
hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is separated 
and 10% ammomia solution is added to it. Pink colour indicates presence of glycosides. 
Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added followed 
by addition of few drops of conc. Sulfuric acid. Appearance of yellow color indicates the 
presence of Flavonoids. 
Test for phenols: 
Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was added.  A 
bulky white precipitate indicated the presence of phenolic compounds. 
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Test for steroids: 
To the test sample , 2ml of chloroform was added with few drops of conc. Sulphuric 
acid (3ml), and shaken well. The upper layer in the test tube was turns into red and sulphuric 
acid layer showed yellow with green fluorescence. It showed the presence of steroids. 
Triterpenoids  
Liebermann–Burchard test: To the chloroform solution, few drops of acetic anhydride 
was added then mixed well. 1 ml concentrated sulphuric acid was added from the sides of the 
test tube, appearance of red ring indicates the presence of triterpenoids. 
Test for Cyanins 
A. Aanthocyanin: 
To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min at 100C. 
Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic’s reagent is added. The mixture is heated 
on a boiling water bath for 2 minutes. A characteristic coloured precipitate indicates the 
presence of sugar. 
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RESULTS 
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ANNEXURE IV 
TOXICOLOGICAL STUDY 
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ANNEXURE -IV 
Evaluation of the siddha drug Thetran Ilagamfor its toxicological in 
Wistar Albino rats 
ACUTE ORAL TOXICITY-EXPERIMENT PROCEDURE: 
 
AcutetoxicitystudieswerecarriedoutaccordingtotheOECD(Organizationof 
Economic Co-operation and Development) guidelines 423. Healthy female rats, weighing 
150–200g,wereselectedandoraladministrationofthesingledosesofThetran Ilagam 
weredoneasepticallybysuspendingin1%SCMC(Sodiumcarboxymethylcellulose). 
Administration of doses: 
 
Thetran Ilagam in1%SCMCwasadministeredasasingleoraldosebygavageusinga 
feedingneedle.Animalswerefastedpriortodosing.Followingtheperiodoffasting,the 
animalswereweighedandthenthetestsubstancewasadministered.Afterthesubstance has 
been administered, food was withheld for a further 3-4 hours. The principle of 
laboratoryanimalcarewasfollowed.Observationsweremadeandrecordedsystematically 
andcontinuouslyobservedaspertheguidelineaftersubstanceadministration.Anoral(p.o) 
doseof5mg/kg,50mg/kg,300mg/kgand2000mg/kgwasadministeredstepbystep 
accordingtotheguidelines.Thegeneralbehaviorsoftheratswerecontinuouslymonitored 
for1hafterdosing,periodicallyduringthefirst24h(withspecialattentiongivenduringthe 
first 4 hours and then daily thereafter, for a total of 14 days. Changes in the normal 
psychomotor activity and external morphology and their body weights weremonitored 
periodicallybeforedosingandthetimeatwhichsignsoftoxicityormortalitywererecorded. 
Thevisualobservationsincludedskinchanges,mobility,aggressively,sensitivityto 
soundandpain,aswellasrespiratorymovements.Theyweredeprivedoffood,butnot 
water12hpriortotheadministrationofthetestsubstance.Finally,thenumberofsurvivors 
wasnotedafter24handtheseanimalswerethenmaintainedforafurther14daysand 
observationsmadedaily.Thetoxicologicaleffectwasassessedonthebasisofmortality. 
Number of animals and dose levels: 
 
Three animals are used for each step. The dose level used as the starting dose 
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Groups No. of Rat 
Group I:  Vehicle control           3 Female 
Group V: test drug – 2000 mg/kg b.wt 6Female 
       TOTAL NO= 9(F) 
OBSERVATIONS: 
 
Animals were observed individually after dosing at least once during the first 
30 minutes, periodically during the first 24 hours, with special attention given during 
the first 4 hours, and daily thereafter, for a total of 14 days, except where they need to 
be removed from the study and humanely killed for animal welfare reasons or are 
found dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. Observations include 
changes in skin and fur, eyes and mucous membranes, and also respiratory, 
circulatory, autonomic and central nervous systems, and somato motor activity and 
behavior pattern. Attention was directed to observations of tremors, convulsions, 
salivation, diarrhea, lethargy, sleep and coma. The principles and criteria summarized 
in the Humane Endpoints Guidance Document taken into consideration. Animals 
found in a moribund condition and animals showing severe pain or enduring signs of 
severe distress was humanely killed. When animals are killed for humane reasons or 
found dead, the time of death should was recorded. 
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4 hours observation in acute toxicity studies 
 
 
 
Parameters observed I
st
hr II
nd
hr III
rd
h
r 
IV
th
hr 
Aggressiveness + + + + 
Alertness - - - - 
Alopecia - - - - 
Circling - - - - 
Diarrhoea - - - - 
Edema - - - - 
Eye closure at touch + + + + 
Grip strength + + + + 
Grooming + + + + 
Lacrimation - - - - 
Loss of writhing reflex - - - - 
Mortality - - - - 
Nasal sniffing - - - - 
Piloerection - - - - 
Rearing - - - - 
Righting reflex - - - - 
Seizures - - - - 
Straub tail - - - - 
Urine stains - - - - 
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14 days observation in acute toxicity studies 
Evaluation of the siddha drug Thuthuvalai legiyam for its toxicological and Spermatogenic activity in Wistar Albino rats 
Parameters observed Day-1 Day-2 Day-3 Day-4 Day-5 Day-6 Day-7 Day-8 Day-9 Day-10 Day-11 Day-12 Day-13 Day-14 
Aggressiveness + + + + + + + + + + + + + + 
Alertness - - - - - - - - - - - - - - 
Alopecia - - - - - - - - - - - - - - 
Circling - - - - - - - - - - - - - - 
Diarrhoea - - - - - - - - - - - - - - 
Edema - - - - - - - - - - - - - - 
Eye closure at touch + + + + + + + + + + + + + + 
Grip strength + + + + + + + + + + + + + + 
Grooming + + + + + + + + + + + + + + 
Lacrimation - - - - - - - - - - - - - - 
Loss of writhing reflex - - - - - - - - - - - - - - 
Mortality - - - - - - - - - - - - - - 
Nasal sniffing - - - - - - - - - - - - - - 
Piloerection - - - - - - - - - - - - - - 
Rearing - - - - - - - - - - - - - - 
Righting reflex - - - - - - - - - - - - - - 
Seizures - - - - - - - - - - - - - - 
Straub tail - - - - - - - - - - - - - - 
Urine stains - - - - - - - - - - - - - - 
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Repeated dose 90-days sub-chronic oral toxicity study of Thetran Ilagam 
on rats 
(OECD – 408 guidelines) 
 
Test Substance : Thetran Ilagam (TI) 
 
Animal Source : Tamil Nadu Veterinary and Animal Sciences 
University 
Animals : Male and Female Wistar Albino Rats 
Age : More than 6 weeks 
Acclimatization : Seven days prior to dosing. 
Veterinary 
examination 
: Priortoandattheendoftheacclimatizationperiod. 
Identification of 
animals 
: Bycagenumber,animalnumberandindividual 
marking onfur. 
Diet : Pelleted feed supplied by Saimeera foods Pvt Ltd, 
Bangalore 
Water : Aqua guard portable water in polypropylene bottles 
ad libitum. 
Housing 
&Environment 
: The animals were housed in Polypropylene cages 
provided with bedding of husk. 
Housing temperature : Between 20 & 24°C, 
Relative humidity : Between 30% and 70%, 
Dark and light cycle : Each of 12 hours. 
 
 
Justification for Dose Selection: 
 
TheresultsofacutetoxicitystudiesinratsindicatedthatThetran Ilagam 
Wasnontoxicandnobehavioralchangeswereobserveduptothe 
doselevelof2000mg/kgbodyweight.Intheliterature,therapeutic dosage for Thetran Ilagam in 
humanis mentionedose is10000mg. 
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Theoralroutewas 
Selectedforusebecauseoralrouteis consideredtobeaproposdtherapeutic route. 
Preparation and administration of dose: 
 
Thetran Ilagam atthreedosesrespectivelywassuspendedinof 
1%SCMCindistilledwater.Itwasadministeredtoanimalsatthedoselevels 
of100and200mg/kg.Thetestsubstancesuspensionswerefreshlyprepared everydayfor90days. 
Thecontrolanimalswereadministeredvehicleonly. 
Administrationwasbyoral(gavage),oncedailyfor90 daysconsecutivedays. 
METHODOLOGY 
 
Randomization, Numbering and Grouping of Animals: 
 
TenRats(FiveMaleandFiveFemale)ineachgrouprandomlydivided 
intothreegroupsfordosingupto90days.Animal’sacclimatizationperiodof 7 days to 
laboratory conditions prior to the initiation of treatment. Each 
animalwasfurmarkedwithpicricacid.Thefemaleswerenulliporousand non-pregnant. 
Groups No. of Rats 
Group I:  control Vehicle  20(10M+ 10F) 
GroupII: test drug (Thetran Ilagam)- Low dose (900mg/kgb.wt) 20(10M + 10F) 
GroupIII: test drug(Thetran Ilagam) - Mid dose (1800mg/kgb.wt) 20(10M + 10F) 
GroupIV: test drug(Thetran Ilagam) High dose (3600mg/kgb.wt) 20(10M + 10F) 
  Total   80 (40 Female + 40 
Male) 
 
OBSERVATIONS: 
 
Experimental animals were kept under observation throughout the course of study for the 
following: 
Body Weight: 
 
Weight of each ratwas recorded on day 0 and at 5 days intervals 
throughoutthecourseofstudyandatterminationtocalculaterelativeorgan 
weights.Fromthedata, groupmeanbodyweightsandpercentbodyweightgain 
werecalculated. 
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Clinical signs: 
 
Allanimalswereobserveddailyforclinicalsigns.Thetimeofonset, 
intensityanddurationofthesesymptoms,ifany,wererecorded. 
Mortality: 
 
Allanimalswereobservedtwicedailyformortalityduringentirecourse ofstudy. 
TERMINAL STUDIES: 
 
Laboratory Investigations: 
 
Following laboratory investigations were carried out on day 91 in animals’ 
fasted over-night. On 91th day, the animals were fasted for 
approximately18h,thenslightlyanesthetizedwithetherandbloodsamples 
werecollectedfromtheretro-orbitalplexusintotwotubes:onewithEDTAfor immediate 
analysis of haematological parameters, the other without any anticoagulant and was 
centrifuged at 4000 rpm at 4 °C for 10 minutes to 
obtaintheserum.Serumwasstoredat20°Cuntilanalyzedforbiochemical parameters. 
Haematological Investigations: 
 
Blood samples of control and experimental rats was analyzed for 
hemoglobincontent,totalredbloodcorpuscles(RBC),whitebloodcorpuscles 
(WBC)count,Meancorpuscularvolume(MCV)andpackedcellvolume(PCV). 
FromtheestimatedvaluesofRBCcount(millions/mm3)andPCV(volumes 
percent),meancorpuscularvolume(MCV)wascalculated. 
Biochemical Investigations: 
 
Serum and Urine was used for the estimation ofbiochemical 
parameters.Samplesofcontrolandexperimentalmicewereanalyzedfor 
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protein, bilirubin, urea, uric acid, creatinine, triglyceride, cholesterol and 
glucoselevelswascarriedusingstandardmethods.Activitiesofglutamate oxaloacetate 
transaminase/ Aspartate aminotransferase (GOT/AST), 
glutamatepyruvatetransaminase/Alanineaminotransferase(GPT/ALT)and 
alkalinephosphatasewereestimatedasperthecolorimetricprocedure. 
Necropsy: 
 
Alltheanimalsweresacrificedonday91.Necropsyofallanimalswas 
carriedoutandtheweightsoftheorgansincludingliver,kidneys,adrenals, 
spleen,brain,heart,uterusandtestes/ovarieswererecorded.Therelative 
organweightofeachanimalwasthencalculatedasfollows; 
Absolute organ weight (g) 
 
Relativeorganweight= ×100 
 
Body weight of rats on sacrifice day (g) 
 
 
 
 
Histopathology: 
 
Histopathologicalinvestigationofthevitalorganswasdone.Theorgan pieces(3-
5µmthick)ofthehighestdoselevelof400mg/kgwerepreserved 
andwerefixedin10%formalinfor24handwashedinrunningwaterfor24h. 
Samplesweredehydratedinanautotechniconandthenclearedinbenzene 
toremoveabsolutealcohol.Embeddingwasdonebypassingthecleared 
samplesthroughthreecupscontainingmoltenparaffinat50°Candthenina cubical block of 
paraffin made by the “L” moulds. It was followed by 
microtomeandtheslideswerestainedwithHaematoxylin-eosin. 
Theorgansincludedbrain,heart,kidneys,liverandlungsoftheanimals 
werepreservedtheyweresubjectedtohistopathologicalexamination. 
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Statistical analysis: 
 
Findingssuchasclinicalsignsofintoxication,bodyweightchanges, 
foodconsumption,hematologyandbloodchemistryweresubjectedtoOne- way Anova. 
Followed by dunnet ’t’ test using a computer software 
programme.(GraphPadPrism5.0) 
166 
 
Repeated dose 90-days sub-chronic oral toxicity study of Thetran Ilagam 
on rats 
 
 
Effect of  Thetran Ilagam on Biochemical parameters 
 
 
 
Dose (mg/kg) Control LD MD HD 
     
Total cholesterol(mg/dl) 111.26±1.16 148.9±22.3 151.95±19.8 148.2±20.8 
     
HDL(mg/dl) 60.5±4.08 69.1±12.8 63.16±5.40 65±10.8 
     
LDL(mg/dl) 31.16±5.03 60±20.8 60.16±13.6 63±12.39 
     
VLDL(mg/dl) 16.43±2.72 19.8±6.2 23.26±5.51 17.95±6.24 
     
Triglycerides(mg/dl) 49.66±2.33 42.6±16.1 42.08±10.18 46.41±9.1 
     
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
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Effect of Thetran Ilagam on Haematological Parameters 
 
 
Parameter Control LD MD HD 
     
RBC(×10
6
µl) 4.08±0.09 6.57±1.17 6.51±1.15 5.98±0.4 
WBC(×10
3
µl) 8.93±0.48 10.01±2.7 9.91±2.1 9.84±1.7 
PLT(×10
3
µl) 792.8±93.33 819.16±134.5 710.41±73.4 705.75±123.08 
HGB(g/dl) 12.5±0.74 13.27±1.4 12.95±2.02 13.6±1.5 
Neutrophils 10
3
/mm
3 
2.01±0.47 2.78±0.71 2.65±0.84 2.30±0.67 
Lymphocyte(%) 76.4±1.52 78.2±9.88 72.59±11.1 74.4±10.2 
Monocyte(%) 3.18±0.11 2.69±0.61 3.41±1.09 3.6±0.95 
Eosinophils(%) 1.3±0.15 1.44±0.21 1.36±0.23 1.42±0.18 
Basophils(%) 0.66±0.51 0.25±0.45 0.25±0.62 0.5±0.52 
MCH(pg) 20.95±1.0 20.2±1.96 18.4±3.1 19.10±2.7 
MCV(fl) 62.06±2.65 61.39±7.7 60.55±7.22 62.9±6.7 
 
Values are mean± S.D. (Dunnett’s test).*P<0.05,**P<0.01,N=12 
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Dose 
 
Relative Organ Weight of rats 
Liver Kidney Brain Lungs Heart Spleen 
 
Control 
 
2.8±0.1 
 
0.66±0.02 
 
0.38±0.22 
 
0.29±0.01 
 
0.29±0.01 
 
0.15±0.01 
 
900mg/kg 
 
2.9±0.1 
 
0.66±0.02 
 
0.40±0.01 
 
0.31±0.02 
 
0.30±0.01 
 
0.16±0.01 
 
3600mg/kg 
 
3.0±0.1 
 
0.67±0.03 
 
0.43±0.01 
 
0.32±0.01 
 
0.31±0.01 
 
0.17±0.01 
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HISTOPATHOLOGICAL INVESTIGATION OF CONTROL AND 
AGC TREATED ANIMALS UNDER MAGNIFICATION POWER 
40X FOR 90 DAYS LONG TERM TOXICITY STUDY: 
 
BRAIN 
CONTROL       HIGH DOSE 
    
 
CONTROL: 
Arrangement of the neurons appears intact with no signs of degeneration or apoptotic 
changes in both the sample so cortex region showed normal neurons with polygonal to round cell 
bodies containing dense cytoplasm. 
 
HIGH DOSE: 
Appearance of Hippocampal neurons was normal with dense network o No signs of 
ischemic changes in the cerebral hemisphere 
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 HEART 
          CONTROL    HIGH DOSE 
 
   
 
 
CONTROL: 
 Perfectly -arranged myocardial fibers, clear transverse striation and normal 
structure were observed. 
 Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei 
of muscle fibers appear oval arrangement 
HIGH DOSE: 
 Myocardial cells appears normal with well-defined mycoplasma and prominent 
nucleus and nucleolus 
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LUNGS 
CONTROL      HIGH DOSE 
 
     
 
 
LUNGS: 
CONTROL: 
 Bronchial opening appears regular with no signs of infiltration 
 Appearance of alveolar network was normal 
 Nucleus of type I and II alveolar cells looks normal 
HIGH DOSE: 
 Perivascular region appears normal, Alveolar septa and wall appeared widen and 
normal 
 No signs of lymphocyte cuffing 
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STOMACH 
          CONTROL     HIGH DOSE 
 
    
 
STOMACH: 
CONTROL: 
 Gastric glands, gastric glands including secretary sheath appears normal 
 Normal gastric mucosa containing intact gastric gland cells, parietal cells which 
are spherical cell with deeply stained dark nucleus 
HIGH DOSE: 
 No signs of ulcer and glandular degeneration were observed 
 Appearance of Sub-mucosa and gastric glands appear normal 
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LIVER 
CONTROL       HIGH DOSE 
     
 
 
LIVER: 
 
CONTROL: 
 Rare appearance of Kupffer cells with no evidence of phagocytosis in 
intracytoplasmic region 
 Liver parenchyma appears normal with no evidence of necrosis 
 Appearance of terminal hepatic venules (central veins) to the portal tracts was 
normal 
HIGH DOSE: 
 Apparent loss of liver parenchyma were observed 
 Increase distant of liver sinusoids were observed 
 Occasional presence of Kupffer cells with no evidence of phagocytosis in 
intracytoplasmic region 
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KIDNEY 
CONTROL      HIGH DOSE 
 
     
 
KIDNEY: 
CONTROL: 
 Appearance of Podocytes and parietal epithelium in the glomeruli appears normal 
 Proximal and distal convoluted tubule appears normal 
 No signs of lesion or inflammation were observed 
 No signs of cellular necrosis 
HIGH DOSE: 
 Some renal tubules appears hypertrophic 
 Appearance of Podocytes and parietal epithelium in the glomeruli appears normal 
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SPLEEN 
CONTROL      HIGH DOSE 
 
    
 
 
 
SPLEEN: 
CONTROL: 
 No signs of perivascular inflammation 
 Appearance of splenic sinuses, Splenic cord and endothelial orientation was 
normal 
 Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath was 
normal with no significant signs of enlargement 
HIGH DOSE: 
 Marginal vascular zone radiated in between red and white pulp 
 Appearance of splenic red pulp was normal 
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CONTROL                   TESTIS  HIGH DOSE 
    
TESTES: 
 
CONTROL: 
 Histocytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
 Appearance of leydig cells, interstitial tissue, seminiferous tubule, Sertoli cells 
and spermatogonia were normal 
HIGH DOSE: 
 Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
 Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells 
And spermatogonia were normal 
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UTERUS 
CONTROL      HIGHDOSE 
    
 
CONTROL: 
 Appearance of endometrium, myometrium and uterine glands was normal.  
 
HIGH DOSE: 
 Appearance of endometrium, myometrium and uterine glands was normal 
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OVARY 
CONTROL     HIGHDOSE 
    
 
 
 
 
 
 
OVARY: 
CONTROL: 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and 
primordial follicles with few mature ovarian follicles with no signs of abnormality. 
HIGH DOSE: 
 Appearance of antral follicle, primary oocyte and secondary follicles are normal 
 
 
 
179  
DISCUSSION 
Oral toxicity evaluation using a 90-days toxicity test is an accustomed practice 
in a Repeated dose 90-days sub-chronic oral toxicity study. Repeated dose 90-days 
sub-chronic oral toxicity studyhas been advocated as a fundamental test for assessing 
safety and has been applied previously in many safety assessment studies. In this 
report, we have first indicated that no dose-related toxicity effect was observed and 
the biochemistry parameters all fell within the reference range. 
Although the body weights were increased during breed period, there were no 
significant different (P > 0.05) of body weights in male and female rats or between 
treatment and control groups. The RBC and coagulation parameters did not show any 
biologically or statistically significant differences between rats treated or controls. 
However, slight decreases (but have no dose dependent effect) in lymphocytes and 
neutrophils were noted in rats treated while these data also fell within the reference 
values. 
In hematological and biochemical examination, some parameters differed in 
male and female SB groups but neither of these appeared to be of toxicological 
significance as they were slightly upper or lower than those of the control groups 
Furthermore no dose related histopathological changes were observed. Gross 
examination in necropsy and at microscopic examination revealed no changes that 
attribute to the administration of drug. 
Compared with concurrent controls, rats fed with Thetran Ilagamshowed 
slight changes in some clinical chemistry and hematology values at various dosages 
but these were not regarded to represent adverse effects of the test substance because 
these values fell within the reference values besides lower cholesterol and triglyceride 
values. ALT and AST are important serum enzymes in the human liver and usually 
helps detect chronic liver diseases by monitoring theirconcentrations. 
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In the present study, results showed that the concentration of ALT and AST 
maintained regardless if the rats were fed with SB or without in treatment or control 
groups. The organ-to-weight ratio is one of the fundamental judgments to diagnose 
whether the organ exposed to the injury or not. Impaired organ often have abnormal 
tumidity or atrophy. There were no significant different (P > 0.05) changes of organ- 
to-weight ratios in male and female rats or between treatment and control groups. 
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CONCLUSION 
 
Treating Wister albino rats with Thetran Ilagamat levels of LD 900, MD1800 
and HD 3600 mg/kg/day to male and female rats for 12 weeks did not cause death and 
was not associated with adverse effects in general condition, growth, body and organ 
weights, hematology and clinical chemistry values, nor did it cause abnormalities in 
necropsy and histopathology findings. According to these results, Thetran Ilagam 
could be categorized as no-observed-adverse-effect level (NOAEL) drug as it acts 
harmlessly under the current normal usage and this phenomenon is considered to be of 
no toxicological concern. The dosage 900,1800 and 3600 mg/kg /day to rats under the 
conditions of this study. This study is first to investigate the toxicity of Thetran 
Ilagamin rats in a 90-daysRepeated dose sub-chronic oral toxicity studytrial and offer 
useful scientificknowledge. 
 
 
 
 
Reference: 
 
 
 
1. Schlede E., Mischke U., Diener W. and Kayser D. The International 
Validation Study of the Acute-Toxic-Class Method (oral). Arch. Toxicol. 
1994;69, 659-670 
2. Schlede E., Mischke U., Roll R. and Kayser D. A National Validation Study  
of the Acute-Toxic-Class Method – an alternative to the LD50 test. Arch. 
Toxicol. 1992;66:455-470. 
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STATISTICAL ANALYSIS 
 
 All collected data were entered into MS Excel software using different columns as 
variable and rows as patients.SPSS software was used to perform statistical analysis.Basic 
descriptive statistics include frequency distributions and cross-tabulations were  performed.The 
quantity variable were expressed as Mean ± Standard Deviation and qualitative data as 
percentage.A probability value of <0.05 was considered to indicate as statistical singnificance 
.Paired “t”test was performed for determining the significance between before and after treatment. 
 
 
Paired Sample Statistics (Group –I Medicine only) before and after treatment  
 
Semen analysis Mean± SD t Value P Value 
Before treatment   12.8  ± 7.06064 9.069 < 0.0001 
After treatment 38.85±19.46461 
 
The mean± standard deviation of Group I Patients Semen Analysis at before and after 
treatment were   12.8  ± 7.0and 38.85±19.46respectively which is statistically significant 
(t=9.069, p=0.0001). 
Sexual Health Score Mean ± SD  t  Value P Value 
Before treatment   6.3± 2.05452 6.8418 < 0.0001 
After treatment 8.4±1.729009 
The mean± standard deviation of Group I Patients Sexual Health Score (SHC) at before 
and after treatment were 6.3± 2.05452 and 8.4±1.729009respectively which is statistically 
significant (t=6.8418, p=0.0001). 
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Paired Sample Statistics (Group –II Medicine along with  Yogamtherapy) before and after 
treatment  
 
 
Semen analysis Mean± SD t Value p Value 
Before treatment 12.8 ±7.06064 5.4025 < 0.0001 
After treatment 38.85±19.46461 
The mean± standard deviation of Group II Patients Semen Analysis at before and after 
treatment were 12.8 ±7.06064and 8.4±38.85± 19.46461respectively which is statistically 
extremely significant (t=5.4025, p=0.0001). 
 
 
The mean± standard deviation of Group II Patients Sexual Health Score (SHC) at before 
and after treatment were 6.15±1.531253and 8.4±10.7±1.454575respectively which is statistically 
extremely significant (t=12.1529, p=0.0001). 
No.of Patients 40 Mean ± SD t Value p Value 
Before treatment 13.275 ± 7.146767   8.9348 <0.0001 
After treatment 46.825 ±23.22011 
 
 
 
 
 
 
Sexual Health Socre Mean± SD t Value p Value 
Before treatment 6.15±1.531253 12.1529 < 0.0001 
After treatment 10.7±1.454575 
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ANNEXURE VII 
CONSENT FORM 
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ANNEXURE -VII 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDASS PANDITHAR HOSPITAL 
TAMBARAM SANATORIUM CHENNAI-47 
Pre clinical and comparative Clinical trial of Thetran Ilagam in the Management of Aan 
Maladu (Male Infertility) 
CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to 
my satisfaction. 
I consent voluntarily to participate in this study and understand that I have the  
right to withdraw from the study at any time without in any way it affecting my further 
medical care”. 
"I have received a copy of the information sheet/consent form". 
 
Date: 
 
Signature of the participant: 
 
In case of illiterate participant 
 
“I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.” 
Date: 
 
Signature ofa witness Left thumb Impression of the Participant 
(Selected by the participant bearing no connection with the surveyteam) 
Date: 
Station: 
Signature of participant: 
 
Signature oftheGuide: Signature of thePrincipal Investigator: 
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ANNEXURE VIII 
CASE SHEET PROFORMA 
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ANNEXURE -VIII 
                                        NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG“THETRAN ILAGAM” (INTERNAL) AND 
“YOGAM THERAPY”  IN THE TREATMENT OF   “AANMALADU” (MALE INFERTILITY) 
Principal Investigator: Dr.S.Karthik Nagarajan 
 
FORM I - SCREENING & SELECTION PROFORMA 
 
1.SERIAL NO: …………………   2. OP /IP NO: ………………… 
3.NAME: ……………………………………      4. AGE/GENDER: ………….......  
5.OCCUPATION: ……………………        6.INCOME: ………………… 
 
INCLUSION CRITERIA 
Male who doesn’t have chance of conception for 1 year after Marriage with frequent 
unprotected sexual intercourse.      YES\ NO 
Age :24-50yrs        YES\ NO 
Sperm count ≤20 million/ml      YES\ NO 
Motility ≤50%       YES\ NO 
Patient willing to undergo Semen analysis &Routine blood investigation before and        
after treatment        YES\ NO 
Willing to participate in trial and signing consent by fulfilling the condition of proforma. 
       YES\ NO 
 
 
EXCLUSION CRITERIA 
Azoospermia         YES\ NO 
Diabetic mellitus        YES\ NO 
VD&STD         YES\ NO 
Inguinal Hernia        YES\ NO 
Vericocele         YES\ NO 
Renal failure         YES\ NO 
Cardiac disease        YES\ NO 
YES  NO  
If Yes, OPD  IPD  
  Serial NO:  
 
Date:        
Station: 
Signature of the Investigator 
Signature of the Lecturer:                                             Signature of the HOD   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
                    DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUGS “THETRAN ILAGAM” (INTERNAL)YOGAM THERAPY 
IN THE TREATMENT OF   “AANMALADU”(MALE INFERTILITY) 
Principal Investigator: Dr.S.KARTHIK NAGARAJAN 
 
FORM II-–HISTORY TAKING PROFORMA 
 
STUDY  NO:   OP / IP NO: 
NAME: AGE / GENDER: 
ADDRESS: CONTACT NO : 
 RELIGION :  H / C / M / O. 
OCCUPATION: INCOME: 
MARITAL STATUS :        Married  
DATE OF INTIAL ASSESSMENT:  
COMPLAINTS & DURATION:   
                                                                                                                                                                              
PERSONAL HISTORY: 
PERSONAL HABITS YES NO 
IF YES 
SPECIFY 
DURATION 
AMOUNT/Qty 
Smoking     
Tobacco Chewing     
Alcohol     
Narcotic  Drug Addiction    
 
 
Working in Hot  Atmospere     
 
HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
 
Past how many years you got married? 
 
 1. Yes            2. No    
 
III.SEXUAL HISTORY 
Do you have trouble getting an erection?              Yes 
No  
Do you have trouble maintaining an erection?                                                    
Yes No Do you have trouble with ejaculations? Yes 
No If yes,____Premature ejaculations   
____Retrograde ejaculations  Do you have any 
abnormal discharge from your penis? Yes /No How 
1._________________ 
 
2._________________ 
 
 
 
 
191  
many times per week do you and your partner have 
intercourse?_____________  
How many times do you have intercourse around 
ovulation?_______________  
Have you recently noticed a change in your sexual 
drive? Yes/no                             Have you had an 
injury or abnormality to your penis,testicles or 
prostate? Yes No If yes,when? _____________ 
Outcome/result_______________ 
IV.FAMILY HISTORY Is there a history of hormonal 
disorders in your family?         Yes No If yes,who and 
what 
type?________________________________________ 
Is there a family history of Cystic Fibrosis                      
Yes No   If yes,whom:_____________________ Tay 
Sachs Disease                Yes No   If 
yes,whom:_____________________ Sickle Cell 
Anemia               Yes No   If 
yes,whom:_____________________ 
V.INFERTILITY HISTORY/TREATMENT  
Have you ever been treated for infertility before? Yes 
No If yes,who was your 
physician?_________________________________ 
What cause of infertility was 
diagnosed?____________________________ Is your 
partner currently seeing a doctor for evaluation of 
infertility? Yes No If yes,specify physician name and 
location.______________________________ 
Which of the following tests have you had performed? 
Check all that apply and results. ____Semen Analysis 
When?_________  Results:__________________ 
DIETARY STYLE: 
 
 
 
 
1. Vegetarian    2. Non-vegetarian 
  
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
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FORM II B 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cms]                       :                        
3. Body Temperature [F]       :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min.   : 
6. Heart Rate / min.    : 
7. Respiratory Rate /min.  :   
                                                                                  Yes            No   
8. Pallor   :   
9. Jaundice   :   
10. Clubbing   : 
11. Cyanosis   : 
12. Pedal Oedema   : 
13. Lymphadenopathy      :  
14. Jugular venous pulsation  :   
SYSTEMIC EXAMINATION 
  Cardiovascular system  :  
  Respiratory system   :  
  Gastro-intestinal system  :  
  Central Nervous system  :  
  Urogenital system   :  
Endocrine system  :  
SIDDHA SYSTEM OF EXAMINATION 
1. THEGI (BODY CONSTITUTION): 
1. Vathaudal 
2. Pithaudal 
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3. Kabaudal 
4. Thonthaudal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji(Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
3. KAALAM: 
1. Kaarkaalam (Aavani-Purattasi) 
2. Koothirkaalam (Ippasi-Kaarthigai) 
3. Munpanikaalam (Maargazhi-Thai) 
4. Pinpanikaalam (Maasi-Panguni) 
5. Ilavenilkaalam (Chithirai-Vaigasi) 
6. Muthuvenilkaalam (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam 
2. Rasatham 
3. Thamasam 
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If yesspecify:  
 
 
 
 
 
 
 
 
 
 
FAMILY HISTORY: 
Bowel habit 
Constipation 
 
Sleep 
Insomnia 
: 
 
 
: 
Regular 
 
 
Good 
 
 
 
Disturbed 
 
Presenceof anxiety : 
 
Yes 
  
No 
 
 No. of abortions his wife had: 
 
 
Yes 
 
 
No 
 Cardiovasculardisease : Yes No 
 Tuberculosis : Yes No 
 Others : Yes No 
Ifyesspecify :   
 
HISTORY OF CONGENITAL ANOMALIES 
Cryptorchidism : Yes No 
Hypospadias : Yes No 
DRUG HISTORY 
  
Steroids : Yes No 
Antidepressant : Yes No 
GENERAL EXAMINATION 
  
Physicalbuild : Lean Normal Obese 
Bodyweight : 
  
Temperature : 
  
Pulserate : 
  
Heartrate : 
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PALPATION 
 
Size and Consistencyof testicles : Normal Abnormal 
 
 
PORIPULANGAL (SENSORY ORGANS):          
KANMENDRIYAM (MOTOR ORGANS) : 
 
 
 
 
 
 
 
 
7. KOSANGAL (SHEATH):           
 
 
 
 
 
 
  
 
 
 
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 
Sukkilam / Suronitham Normal  /Affected Normal  /Affected 
 
9. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
 
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
 Before treatment After treatment 
Kai  Normal  /Affected Normal  /Affected 
Kaal Normal  /Affected Normal  /Affected 
Vai Normal  /Affected Normal  /Affected 
Eruvai Normal  /Affected Normal  /Affected 
Karuvai Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Annamayakosam Normal  /Affected Normal  /Affected 
Pranamayakosam Normal  /Affected Normal  /Affected 
Manomayakosam Normal  /Affected Normal  /Affected 
Vignanamayakosam Normal  /Affected Normal  /Affected 
Ananthamayakosam Normal  /Affected Normal  /Affected 
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A) VALI 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
Praanan         
Abaanan         
Samaanan         
Udhaanan         
Viyaanan         
Naagan         
Koorman         
Kirukaran         
Devathathan         
Dhananjeyan         
 
 
B) AZHAL 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
 day 29
th
 day 36
th
 day 43
rd
 day 49
th
 day 
Analakam         
Ranjakam          
Saathakam          
Prasakam          
Aalosakam         
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IYYAM 
 
 0
th
 day 8
th
 day 15
th
 day 22
nd
 day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam         
 
 
 
10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI 0
th
  day 8
th 
day
 
15
th 
day 22
nd
day 29
th
day 36
th
  day 43
rd
day 45
th
day 
         
 
II. SPARISAM: [PALPATION] 
 
Day SPARISAM 
0
th
  day  
8
th 
day
  
15
th
  day  
22
nd
  day  
29
th
  day  
36
th
  day  
43
rd
 day  
49
th 
day  
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III. NAA: [TONGUE] 
 
NAA 0
th
day 8
th
day
 
15
th
day 22
nd
day 29
th
day 36
th
day 43
rd
day 49
th
day 
         
 
IV.NIRAM: [COMPLEXION]   
 1. Vadham         
 2. Pitham 
 3. Kabam 
 
V.MOZHI: [VOICE] 
1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
VI.VIZHI: [EYES] 
VIZHI 0
th
  day 8
th 
day
 
15
th
day 22
nd
day 29
th
day 36
th
  day 43
rd
day 49
th
day 
         
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
 
VIII. MOOTHIRAM [URINE EXAMINATION]  
NEERKKURI: 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
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Enjal   
NEIKKURI:  
 
Neikkuri Before treatment After treatment 
Aravananeedathu/ 
Snake like pattern 
 
  
Azhipolparaviyathu 
Annular/Ringedpattern 
 
 
 
paravparaparavoiyadu 
  
Muththothuninrathu 
Pearlbeadepattern 
  
Other patterns   
 
12. CLINICAL EXAMINATION:    
 
Examination of Genital Organs:    16.Examinatiin of Male Genitalia 
  
 Testis Epididymis Vas deferens  Varicocele Hydrocele Hernia 
Right       
Left       
 
Examination of penis 
Prepuce External urethral meatus Glans penis Body of penis 
    
 
17. CLINICAL SYMPTOMS 
 
S.no CLINICAL 
SYMPTOMS 0th day 12th day 24th day 36th day 45th day 
1 Premature ejaculation      
2 Nocturnal emission      
3 Erectile dysfunction      
4 Painful coitus      
5 Painful micuturition      
 : 
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NATIONAL INSTITUTE OF SIDDHA. 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL TRAIL OF SIDDHA DRUG “THETRAN ILAGAM” (INTERNAL) 
AND “YOGAM THERAPY”  IN THE TREATMENT OF   “AANMALADU” (MALE 
INFERTILITY)  
Principal Investigator: Dr.S.KARTHIK NAGARAJAN 
 
 
 
FORM  -III   CLINICAL ASSESSMENT DURING & AFTER TRIAL 
 
 
1.OP/ IP NO: ………… 2. SL. NO: ……… 3.NAME: ………………………….          
4. AGE: ……… 5. GENDER: …...   6. DATE OF RECRUITMENT: …… 
 
1.  SEMEN ANALYSIS : 
 
Volume: 
Colour : 
pH: 
Viscosity: 
Liquefaction time: 
Motility: 
Viability: For counting viable sperms eosin stain was used in laboratory. 
Gradation of Sperm count: 
Severe Oligozoospermia 
Moderate Oligozoospermia 
Mild Oligozoospermia 
Morphological evaluation: 
 
Testosterone level= 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
201  
FORM- III-A 
SEXUAL HEATH SCORE   
 
Sexual desire                                                                             SCORE 
 No desire at all                    0  
 Lack of desire               1  
  Desire but no activity             2  
Desire only on demand of the partner       3 
 Normal desire               4  
Excess desire                       5   
 
ERECTION 
No erection by any methods                    0 
 Erection with artificial methods          1 
 Erection but unable to penetrate          2 
 Initial difficulty but able to penetrate          3  
Erection with occasional failure            4 
 Erection when ever desired          5   
 
RIGIDITY  
Unable to maintain erection or unable to continue sexual act       0  
Some case in erection but able to continue                  1  
Sexual act to maintain erection and continue sexual act     2   
 
EJACULATION 
 No ejaculation at all             0  
Delayed ejaculation without orgasm          1 
 Ejaculation before penetration           2  
Ejaculation with penetration but early          3  
Discharge ejaculation with own satisfaction          4  
Ejaculation with own and partner’s satisfaction        5   
 
ORGASM 
 
No ejaculation at all             0  
Lack of enjoyment in most of occasions        1  
Enjoyment in 25% of sexual encounters         2  
Enjoyment in 50% of sexual act           3  
Enjoyment in 75% of sexual act                      4  
Enjoyment in every sex act                       5   
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FORM- III-B 
YOGAM THERAPY 
 SERIAL NO: 
  NAME OF THE ASANAM:  
1.Araimachchenthira asanam 
2.Machasanam(meenasanam) 
3.Mahamutra 
4.Sarvaangasanam(muzhu udal asanam) 
5.Shalabhasanam(Vittil asanam) 
6.Dhanurasanam(Vizlasanam) 
7.Pachimothasanam(Thalai muzhangaal asanam) 
8.Pranayamam(Sarapayirchi or Moochu payirchi) 
9.Shanthiasanam(Savasanam) 
 
 
 
   Day    Date          Morning         Evening 
Day 0    
Day 8    
Day 15    
Day 22    
Day 29    
Day 36    
Day 41    
Day 45    
 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the H.O.D 
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MOOTHIRAM 
 
1. Neerkuri 
 
Niram : 
 
Manam : 
 
Edai : 
 
Nurai : 
 
Enjal : 
 
2. Neikuri 
 
SIGNS AND SYMPTOMS: 
 
S.N 
o 
Clinical Features Before 
Treatment 
During Treatment of every 7days 
        
1. Premature 
ejaculation 
         
2. Erectile dysfunction          
3. Painful coitus          
4. Nocturnal emission          
5. Burning micturition          
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
        AN OPEN CLINICAL TRIAL OF SIDDHA DRUGS “THETRAN ILAGAM” (INTERNAL) AND 
“YOGAM THERAPY IN THE TREATMENT OF   “AANMALADU” (MALE INFERTILITY)  
 
Principal Investigator: Dr.S.KARTHIK NAGARAJAN                                                               
 
FORM-IV - LABORATORY INVESTIGATIONS 
 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE TMT 
( DATE) 
AFTER TMT 
(DATE) 
Hb (gm/dl) 
M:12-15 
W:11.5-12 
  
T.WBC (cells/cu.mm) 4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 
T.RBC (million cells / cu.mm) 
 
M:4.0-5.5 
W:3.5-4.5 
 
 
 
 
ESR (mm/hour) ½ hr. 
M:6-12 
W:7-18 
  
  1 hr.  
 
 
Blood glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Random 80-120   
RFT (mg/dl) 
Blood urea 16-50   
Serum Creatinine 0.6-1.2   
LFT (mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-1.2   
Indirect bilirubin 0.2-0.7   
SGOT 0-40   
SGPT 0-35   
Alkaline phosphatase 80-290   
SPECIFIC INVESTIGATION 
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  SEMEN ANALYSIS –   
 Volume 
 Colour  
 Appearance 
 Viscosity 
 Liquification time 
 Fructose 
 Sperm count 
 Motility 
 Morphology 
Testosterone level= 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
 
URINE INVESTIGATION BEFORE TMT( DATE) AFTER TMT ( DATE) 
Albumin   
Fasting sugar   
PP sugar   
Deposits   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
. AN OPEN CLINICAL TRIAL OF SIDDHA DRUGS “THETRAN ILAGAM” (INTERNAL) 
AND YOGAM THERAPY IN THE TREATMENT OF   “AANMALADU (MALE INFERTILITY) 
     
FORM-V– INFORMATION SHEET 
 
Name of Principal Investigator  :  Dr.S.KARTHIK NAGARAJAN 
Name of the institute                   : National Institute of Siddha, 
                                                         Tambaram Sanatorium, 
                                                         Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN CLINICAL 
TRIAL: 
I, Dr.S.KARTHIK NAGARAJAN Studying as M.D(Siddha) at National Institute of  
Siddha, Tambaram Sanatorium is doing a trial on the study AANMALADU (MALE 
INFERTILITY) MALE INFERTILITY  is a most common   disease in now a days, occurring 
throughout the world. In this regard, I am in a need to ask you few questions. I will maintain 
confidentiality of your comments and data obtained. There will be no risk of disclosing your 
identity and no physical, psychological or professional risk is involved by taking part in this 
study. Taking part in this study is voluntary. No compensation will be paid to you for taking part 
in this study. 
           You can choose not to take part. You can choose not to answer a specific question. There 
is no specific benefit for you if you take part in the study. However, taking part in the study may 
be of benefit to the community, as it may help us to understand the problem of defaulters and 
potential solutions. 
             If you agree to be a participant in this study, you will be included in the study primarily 
by signing the consent form and then you will be given the internal medicine Thetran lehiyam  
(Internal medicine-5gm, Twice a Day with milk  for 45 days) and yogam therapy, if you wish to 
stay in the In Patient ward  Treatment will be provided to you assuring that you will not be 
definitely hurt in any course of treatment. 
 The information I am collecting in this study will remain between you and the principal 
investigator (myself).  
            If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.S.Karthik Nagarajan, PG Scholar cum principal investigator of 
this study, attached to National Institute of Siddha, Chennai-47. You can also contact the 
Member-secretary of Ethics committee, National Institute Siddha,Chennai 600047, Tel no : 91-
44-22380789, for rights and participation in the study. 
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FORM-V  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
. AN OPEN CLINICAL TRIAL OF SIDDHA DRUGS “THETRAN ILAGAM” (INTERNAL) AND 
“YOGAM THERAPY IN THE TREATMENT OF   AANMALADUI” (MALE INFERTILITY) 
 
Name of Principal Investigator: Dr.S.KARTHIK NAGARAJAN     
FORM –IV- DRUG COMPLIANCE FORM 
SERIAL NO: 
NAME:  
DRUG NAME:  
On 1
st    
 day-Date:  Drugs issued: (Gms) Drugs returned:    (Gms) 
On 8
th
   day-Date:   Drugs issued: (Gms) Drugs returned:    (Gms) 
On 15
th
 day-Date:              Drugs issued: (Gms) Drugs returned:    (Gms) 
On 22
th
 day-Date:           Drugs issued: (Gms) Drugs returned:    (Gms) 
On 29
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 36
th
 day-Date:              Drugs issued: (Gms) Drugs returned:    (Gms) 
On 42
th
 day-Date:              Drugs issued: (Gms) Drugs returned:    (Gms) 
On 45
th
 day Date  Drugs issued: (Gms) Drugs returned:    (Gms) 
 
 
 
 
   Day    Date          Morning   Evening   Day    Date    Morning   Evening 
Day 1    Day25    
Day2    Day26    
Day3    Day27    
Day4    Day28    
Day5    Day29    
Day6    Day30    
Day7    Day31    
Day8    Day32    
Day9    Day33    
Day10    Day34    
Day11    Day35    
Day12    Day36    
Day13    Day37    
Day14    Day38    
Day15    Day39    
Day16    Day40    
Day17    Day41    
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Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day18    Day42    
Day19    Day43    
 
Day20    Day44    
Day21    Day45    
Day22        
Day23        
Day24        
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Name of Principal Investigator: Dr.S.KARTHIK NAGARAJAN      
 
FORM VII - WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE:    
2. OP / IP NO:    
3. NAME:     
4. AGE:         
5. GENDER:                          
6. DATE OF TRIAL COMMENCEMENT:  
7. DATE OF WITHDRAWAL FROM TRIAL:  
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                              Yes/No 
(If YES, give the details of adverse reaction in Form VII -B – Adverse      Reaction 
Form / Pharmaco Vigilance Form) 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         Signature of the HOD 
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FORM VII - A – ADVERSE REACTION FORM / PHARMACO VIGILANCE FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
 
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
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FORM VIII – DIETARY ADVICE FORM 
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